CURRICULUM VITAE

ACADEMIC, SCIENTIFIC AND WORK ACTIVITIES OF

DR. MARIACRISTINA DI MARCO

- CONFIRMED RESEARCHER ON MEDICAL ONCOLOGY -

- SCIENTIFIC DISCIPLINARY SECTOR MED/06 -

Department of Reference: DIMES

Alma Mater Studiorum Bologna

**CURRICULUM VITAE**

## Titles

* **Degree in Medicine and Surgery** obtained on June 26, 1997 at the University of Bologna with points 110/110 cum laude, experimental thesis entitled "*Hypochloridria and carcinogenesis of the stomach*", supervisor Prof. G. Biasco, with academic qualification as Master's Doctor;
* **Diploma of Specialization in Medical Oncology** obtained on 15/11/01 at the University of Bologna with a vote of 70/70 cum laude with thesis entitled " New methods of treatment of *colorectal cancer: implications* in clinical practice", supervisor Prof. G. Biasco.
* **PhD in Experimental and Clinical Oncology** obtained with a positive result on 18/03/05 at the University of Modena and Reggio Emilia, with thesis entitled "*Chemoprevenzione del cancro del colore retto*".
* Title of **Aggregate Professor of the University of Bologna** since 2006 for having taken teaching positions in degree courses in Physiotherapy, CDL in Obstetrics (AA 2012-2013), school of specialization in Oncology (from 2006 to today), School of Specialization in Health Physics (from 2009 to 2013).
* Since October 1, 2006 Di Marco Mariacristina has been hired at the University of Bologna with the role of **Researcher in Medical Oncology Disciplinary Sector MED/06**. From 01/12/2006 to today Researcher equated with Medical-Oncology Executive integrated for full-time care purposes until 31 May 2015 in the SSD of Medical Oncology Prof. G. Biasco of the Policlinico Sant'Orsola Malpighi, from 1/06/2015 to 31/10/2017 at the Operative Unit of Oncology Continuity Medicine Prof. G. Biasco and from 1/11/2017 until today at the Operative Unit of Medical Oncology Prof. Ardizzoni of the Policlinico Sant'Orsola-Malpighi.
* From October 2006 to all: Qualification of **Aggregate Professor** in the CDL of Physiotherapy, Infirmary of Faenza and CDL Orthopedic Technicians as Professor of Oncology.
* Quality referent from 2006 to 2010 and from 2010 to 31 May 2015 nominated Quality **Manager** **(RDQ)** of the SSD Medical Oncology Prof. Biasco.
* From December 2010 to today: **Researcher confirmed** with the role of Researcher in Medical Oncology Disciplinary Scientific Sector MED/06.
* **Qualification to the Profession of Surgeon** obtained on 15/12/97 at the Faculty of Medicine and Surgery of the University of Bologna; He attended English courses in Italy as a native language teacher and then in England, in 1980 respectively, with the frequency of one month at the Winchester British School of English (accredited British Council) and in 1982 again with the frequency of one month at the Richmond School of English in Birmingham. He also holds the **English Diploma (LevelC1)** awarded by the British Institutes on 08/11/04.

**TEACHING ACTIVITIES**

* Qualification of **Aggregate Professor of Oncology** for training activities from AA 2006-2007 from 01-10-2006 to the present day
* Teaching assignment of **Oncology with primary responsibility** in the CI of Special Rehabilitation II in the CDL of Physiotherapy with consequent attribution **of the title of Aggregate Professor from 01-11-2006 to 31-10-2010**
* Assignment in teaching in **the Area of Medical Oncology for years I, II, III and IV** within the School of Specialization in Oncology of the University of Bologna from 01-11-2006 to the end
* **Scientific coordinator for the University of Bologna of the project "Distance Training" in Oncology (FADO) within the National Interuniversity Consortium** for Bio-Oncology in collaboration with other Universities, including the University of Chieti, Ancona, Aquila from 01-01-2007 to 28-02-2007
* **Assignment of oncology teaching in the school of specialization of Health Physics from 01-11-2009 to 31-10-2010**
* **Teaching assignment in SPECIAL REHABILITATION 2 (C.I.) – ONCOLOGY** Degree course: 0165-**PHYSIOTHERAPY** (ENABLING THE HEALTH PROFESSION OF **PHYSIOTHERAPIST) - Cycle: 5 - Cfu: 1 Hours allocated: 12 hours - Total** hours: 12 hours - Hours held: 12 hours from 01-11-2010 to 31-10-2011
* **Teaching assignment in PROFESSIONAL ACTIVITIES IN MEDICAL ONCOLOGY II - C3 - 1 FRONTAL PART 8252-MEDICAL ONCOLOGY (School of Medical Specialization**) - Cycle: 2 - Cfu: 24 Hours assigned: 43 hours - Total hours: 52 hours - Hours held: 52 hours from 01-11-2011 to 31-10-2012
* Teaching assignment **in PROGRESS OF MEDICAL ONCOLOGY II – ON** MEDICAL ONCOLOGY **2D: 8252-MEDICAL ONCOLOGY** (School of Medical Specialization) - Cycle: 2 - Cfu: 1 Hours assigned: 8 hours - Total hours: 8 hours - Hours held: 8 hours from 01-11-2011 to 31-10-2012
* **Teaching assignment in SPECIAL REHABILITATION 2 (C.I.) – ONCOLOGY Degree course: 0165-PHYSIOTHERAPY (ENABLING THE HEALTH PROFESSION OF**
* **PHYSIOTHERAPIST) - Cycle: 1 - Cfu: 1 Hours allocated: 12 hours - Total hours: 12 hours - Hours held: 12 hours from 01-11-2011 to 31-10-2012**
* **Teaching assignment in PROFESSIONAL ACTIVITIES IN MEDICAL ONCOLOGY III - C3 - 1 MODULE 1 frontal** part 8252-MEDICAL ONCOLOGY (School of **Medical Specialization) -** Cycle: 3 - Cfu: 36 Hours assigned: 32 hours - Total hours: 32 hours - Hours held: 32 hours from 01-11-2011 to 31-10-2012
* **Teaching assignment in THE COURSE INTEGRATED MEDICAL ONCOLOGY IV -** MEDICAL ONCOLOGY 4 Degree course: 8228-MEDICAL PHYSICS (School of Medical Specialization) - Cycle: 4 - Cfu: 1 Hours assigned: 8 hours - Total hours: 16 hours - Hours held: 16 hours from 01-11-2011 to 31-10-2012
* Teaching assignment in PROFESSIONAL ACTIVITIES MEDICAL ONCOLOGY I - C3 - 1 Front Degree course: 8252-MEDICAL ONCOLOGY (School of Medical Specialization) - Cycle: 1 - Cfu: 24 Hours assigned: 22 hours - Total hours: 29 hours - Hours held: 29 hours from 01-11-2011 to 31-10-2012
* **Teaching assignment in SPECIAL REHABILITATION 2**(C.I.) – ONCOLOGY **Degree course: 0165-PHYSIOTHERAPY** (ENABLING THE HEALTH PROFESSION OF PHYSIOTHERAPIST) - Cycle: 1 - Cfu: 1 Hours assigned: 12 hours - Total hours: 12 hours - Hours held: 12 hours from 01-11-2012 to 31-10-2013
* Teaching assignment in THE COURSE INTEGRATED MEDICAL ONCOLOGY V - MEDICAL ONCOLOGY 5C Degree course: 8252-MEDICAL ONCOLOGY (School of Medical Specialization) - Cycle: 5 - Cfu: 2 Hours assigned: 16 hours - Total hours: 16 hours - Hours held: 16 hours from 01-11-2012 to 31-10-2013
* Teaching assignment in PROFESSIONAL ACTIVITIES IN MEDICAL ONCOLOGY II - C3 - 1 FRONT Degree course: 8252-MEDICAL ONCOLOGY (School of Medical Specialization) - Cycle: 2 - Cfu: 24 Hours assigned: 43 hours - Total hours: 43 hours - Hours held: 43 hours from 01-11-2012 to 31-10-2013
* Teaching assignment in PROFESSIONAL ACTIVITIES MEDICAL ONCOLOGY I - C3 - 1 Front Degree course: 8252-MEDICAL ONCOLOGY (School of Medical Specialization) - Cycle: 1 - Cfu: 24 Hours assigned: 22 hours - Total hours: 22 hours - Hours held: 22 hours from 01-11-2012 to 31-10-2013
* Teaching assignment in PROGRESS OF MEDICAL ONCOLOGY II - MEDICAL ONCOLOGY 2D Degree course: 8252-MEDICAL ONCOLOGY (School of Medical Specialization) - Cycle: 2 - Cfu: 1 Hours assigned: 8 hours - Total hours: 8 hours - Hours held: 8 hours from 01-11-2012 to 31-10-2013
* Teaching assignment in ENDOCRINOLOGY AND MEDICAL ONCOLOGY (C.I.) – MEDICAL ONCOLOGY Degree course: 0169-OBSTETRICS (ENABLING THE HEALTH PROFESSION OF MIDWIFERY/O) - Cycle: 1 - Cfu: 1 Hours assigned: ASSIGNED 18 hours - Total hours: 19 hours and 40 minutes - Hours kept: 19 hours and 40 minutes from 01-11-2012 to 31-10-2013
* Teaching assignment in PROGRESS OF MEDICAL ONCOLOGY II - MEDICAL ONCOLOGY 2D Degree course: 8252-MEDICAL ONCOLOGY (School of Medical Specialization) - Cycle: 2 - Cfu: 1 Hours assigned: 8 hours - Total hours: 8 hours - Hours held: 8 hours from 01-11-2013 to 31-10-2014
* Teaching assignment in PROFESSIONAL ACTIVITIES IN MEDICAL ONCOLOGY III - C3 - 3 MODULE 3 frontal part Degree course: 8252-MEDICAL ONCOLOGY (School of Medical Specialization) - Cycle: 3 - Cfu: 2 36 Hours allocated: 32 hours - Total hours: 32 hours - Hours held: 32 hours from 01-11-2013 to 31-10-2014
* Teaching assignment in PROGRESS INTEGRATED MEDICAL ONCOLOGY IV - MEDICAL ONCOLOGY 4D Degree course: 8252-MEDICAL ONCOLOGY (School of Medical Specialization) - Cycle: 4 - Cfu: 1 Hours assigned: 8 hours - Total hours: 8 hours - Hours held: 8 hours from 01-11-2013 to 31-10-2014
* Teaching assignment in THE COURSE INTEGRATED MEDICAL ONCOLOGY V - MEDICAL ONCOLOGY 5D Degree course: 8252-MEDICAL ONCOLOGY (School of Medical Specialization) - Cycle: 5 - Cfu: 2 Hours assigned: 16 hours - Total hours: 16 hours - Hours held: 16 hours from 01-11-2013 to 31-10-2014
* Teaching assignment in PROGRESS INTEGRATED MEDICAL ONCOLOGY V - MEDICAL ONCOLOGY 5C Degree course: 8252-MEDICAL ONCOLOGY (School of Medical Specialization) - Cycle: 5 - Cfu: 2 Hours assigned: 16 hours - Total hours: 16 hours - Hours held: 16 hours from 01-11-2013 to 31-10-2014
* Teaching assignment in PHARMACOLOGY, PSYCHIATRY, ONCOLOGY (C.I.) – ONCOLOGY Degree course: 8476-PHYSIOTHERAPY (ENABLING THE HEALTH PROFESSION OF PHYSIOTHERAPIST) - Cycle: 3 - Cfu: 2 Hours assigned: 24 hours - Total hours: 24 hours - Hours held: 24 hours from 01-11-2013 to 31-10-2014
* Teaching assignment in PROGRESS OF MEDICAL ONCOLOGY III - MEDICAL ONCOLOGY 3D Degree course: 8252-MEDICAL ONCOLOGY (School of Medical Specialization) - Cycle: 3 - Cfu: 1 Hours assigned: 8 hours - Total hours: 8 hours - Hours held: 8 hours from 01-11-2013 to 31-10-2014
* Teaching assignment in THE COURSE INTEGRATED MEDICAL ONCOLOGY V - MEDICAL ONCOLOGY 5C Degree course: 8252-MEDICAL ONCOLOGY (School of Medical Specialization) - Cycle: 5 - Cfu: 2 Hours assigned: 16 hours - Total hours: 16 hours - Hours held: 16 hours from 01-11-2014 to 31-10-2015
* Teaching assignment in HOLISTIC MANAGEMENT OF ONCOLOGY PATIENTS AT HOME (C.I.) - ONCO-HEMATOLOGY Degree course: 8474-NURSING (ENABLING THE HEALTH PROFESSION OF NURSE) - Cycle: 3 - CFu: 1 Hours allocated: 12 hours - Total hours: 12 hours - Hours held: 12 hours from 01-11-2014 to 31-10-2015
* Teaching assignment in PHARMACOLOGY, PSYCHIATRY, ONCOLOGY (C.I.) – ONCOLOGY Degree course: 8476-PHYSIOTHERAPY (ENABLING THE HEALTH PROFESSION OF PHYSIOTHERAPIST) - Cycle: 1 - Cfu: 2 Hours assigned: 24 hours - Total hours: 25 hours - Hours held: 25 hours from 01-11-2014 to 31-10-2015
* Teaching assignment in HOLISTIC MANAGEMENT OF ONCOLOGY PATIENT AT HOME (C.I.) - PSYCHO-ONCOLOGY Degree course: 8474-NURSING (ENABLING THE HEALTH PROFESSION OF NURSE) - Cycle: 3 - Cfu: 1 Hours allocated: 12 hours - Total hours: 12 hours - Hours held: 12 hours from 01-11-2014 to 31-10-2015
* Teaching assignment in CLINICAL SCIENCES OF THE MEDICAL-SPECIALIST AREA (C.I.) - ONCOLOGY AND PALLIATIVE CARE Degree course: 8474-NURSING (ENABLING THE HEALTH PROFESSION OF NURSE) - Cycle: 2 - CFU: 1 Hours allocated: 12 hours - Total hours: 13 hours - Hours held: 13 hours from 01-11-2014 to 31-10-2015
* Teaching assignment in CLINICAL SCIENCES OF THE MEDICAL-SPECIALIST AREA (C.I.) - ONCOLOGY AND PALLIATIVE CARE Degree course: 8473-NURSING (ENABLING THE HEALTH PROFESSION OF NURSE) - Cycle: 1 - CFU: 1 Hours allocated: 12 hours - Total hours: 12 hours - Hours held: 12 hours from 01-11-2015 to 31-10-2016
* Teaching assignment in MEDICINE 1 C.I. - MEDICAL ONCOLOGY - Degree course: 8479-PODOLOGY (ENABLING THE HEALTH PROFESSION OF PODIATRIST) - Cycle: 2 - Cfu: 1 Hours assigned: 8 hours - Total hours: 9 hours - Hours held: 9 hours from 01-11-2015 to 31-10-2016
* Teaching assignment in SEMINARS - 2 module Medical oncology Degree course: 8483-ORTHOPEDIC TECHNIQUES - MODULE SEMINARI WITH DIDACTIC RESPONSIBILITY OF THE ENTIRE TRAINING ACTIVITY (ENABLING THE HEALTH PROFESSION OF ORTHOPEDIC TECHNICIAN) - Cycle: 1 - CFU: 6 Hours allocated: 24 hours - Total hours: 24 hours - Hours held: 24 hours from 01-11-2015 to 31-10-2016
* Teaching assignment in CLINICAL SCIENCES OF THE MEDICAL-SPECIALIST AREA (C.I.) - ONCOLOGY AND PALLIATIVE CARE Degree course: 8474-NURSING (ENABLING THE HEALTH PROFESSION OF NURSE) - Cycle: 1 - CFU: 1 Hours allocated: 12 hours - Total hours: 12 hours - Hours held: 12 hours from 01-11-2015 to 31-10-2016
* Teaching assignment in PHARMACOLOGY, PSYCHIATRY, ONCOLOGY (C.I.) – ONCOLOGY Degree course: 8476-PHYSIOTHERAPY (ENABLING THE HEALTH PROFESSION OF PHYSIOTHERAPIST) - Cycle: 1 - Cfu: 2 Hours assigned: 24 hours - Total hours: 24 hours - Hours held: 24 hours from 01-11-2015 to 31-10-2016
* Teaching assignment in HOLISTIC MANAGEMENT OF ONCOLOGY PATIENT AT HOME (C.I.) - PSYCHO-ONCOLOGY Degree course: 8474-NURSING (ENABLING THE HEALTH PROFESSION OF NURSE) - Cycle: 1 - Cfu: 1 Hours allocated: 12 hours - Total hours: 12 hours - Hours held: 12 hours from 01-11-2015 to 31-10-2016
* Teaching assignment in HOLISTIC MANAGEMENT OF ONCOLOGY PATIENT AT HOME (C.I.) - ONCO-HEMATOLOGY Degree course: 8474-NURSING (ENABLING THE HEALTH PROFESSION OF NURSE) - Cycle: 1 - Cfu: 1 Hours allocated: 12 hours - Total hours: 12 hours - Hours held: 12 hours from 01-11-2015 to 31-10-2016
* Teaching assignment of Medical Oncology at the OTOLARYNGOLOGY Specialization School from A.Y. 2016-2017 from 01-09-2016 to 31-08-2017
* Teaching assignment in PHYSIOTHERAPY (ENABLING THE HEALTH PROFESSION OF PHYSIOTHERAPIST) - Cycle: 1 - Cfu: 2 Hours assigned: 24 hours from 01-11-2016 to 31-10-2017
* Teaching assignment in NURSING (QUALIFIED FOR THE HEALTH PROFESSION OF NURSES) - Cycle: 1 - Cfu: 1 Hours assigned: 12 hours from 01-11-2016 to 31-10-2017
* Teaching in NURSING (ENABLING THE HEALTH PROFESSION OF NURSES) - Cycle: 1 - CFU: 2 Hours assigned: 24 hours from 01-11-2016 to 31-10-2017
* Teaching assignment in ORTHOPEDIC TECHNIQUES - SEMINARS MODULE WITH EDUCATIONAL RESPONSIBILITY OF THE ENTIRE TRAINING ACTIVITY (ENABLING THE HEALTH PROFESSION OF ORTHOPEDIC TECHNICIAN) - Cycle: 1 - CFU: 6 Hours assigned: 24 hours from 01-11-2016 to 31-10-2017
* Teaching assignment in NURSING (QUALIFIED FOR THE HEALTH PROFESSION OF NURSES) - Cycle: 1 - Cfu: 1 Hours assigned: 12 hours from 01-11-2016 to 31-10-2017
* Teaching assignment in PODOLOGY (QUALIFIED FOR THE HEALTH PROFESSION OF PODIATRIST) - Cycle: 2 - Cfu: 1 Hours assigned: 8 hours from 01-11-2016 to 31-10-2017
* Teaching assignment in PHYSIOTHERAPY (QUALIFIED IN THE HEALTH PROFESSION OF PHYSIOTHERAPIST) - Cycle: 1 - Cfu: 2 Hours assigned: 24 hours from 01-11-2017 to 31-10-2018
* Teaching in NURSING (ENABLING THE HEALTH PROFESSION OF NURSES) - Cycle: 1 - CFU: 2 Hours assigned: 24 hours from 01-11-2017 to 31-10-2018
* Teaching in the School of Specialization Medical Oncology IV - Frontal Teaching - Module 2 - 16 hours from 01-11-2017 to 31-10-2018
* Teaching assignment in PODOLOGY (QUALIFIED FOR THE HEALTH PROFESSION OF PODIATRIST) - Cycle: 2 - Cfu: 1 Hours assigned: 8 hours from 01-11-2017 to 31-10-2018
* Teaching assignment in NURSING (QUALIFIED IN THE HEALTH PROFESSION OF NURSES) - Cycle: 1 - Cfu: 1 Hours assigned: 12 hours from 01-11-2017 to 31-10-2018
* Teaching assignment in ORTHOPEDIC TECHNIQUES - SEMINARS MODULE WITH EDUCATIONAL RESPONSIBILITY OF THE ENTIRE TRAINING ACTIVITY (ENABLING THE HEALTH PROFESSION OF ORTHOPEDIC TECHNICIAN) - Cycle: 1 - CFU: 6 Hours assigned: 24 hours from 01-11-2017 to 31-10-2018
* Teaching assignment in NURSING (QUALIFIED IN THE HEALTH PROFESSION OF NURSES) - Cycle: 1 - Cfu: 1 Hours assigned: 12 hours from 01-11-2017 to 31-10-2018
* Teaching assignment in PODOLOGY (QUALIFIED FOR THE HEALTH PROFESSION OF PODIATRIST) - Cycle: 2 - Cfu: 1 Hours assigned: 8 hours from 01-11-2018 to today
* Teaching in NURSING (ENABLING THE HEALTH PROFESSION OF NURSES) - Cycle: 1 - Cfu: 2 Hours assigned: 24 hours from 01-11-2018 to today
* Teaching assignment in PHYSIOTHERAPY (QUALIFIED IN THE HEALTH PROFESSION OF PHYSIOTHERAPIST) - Cycle: 1 - Cfu: 2 Hours assigned: 24 hours from 01-11-2018 to date 2018/2019 - 04982 - MEDICAL ONCOLOGY (C.I.) - MEDICAL ONCOLOGY - REC Degree course: 8415-MEDICINE AND SURGERY - Cycle: 4 - Cfu: 2 Hours assigned: 16 hours from 01-11-2018 to date
* Teaching assignment in ORTHOPEDIC TECHNIQUES - SEMINARS MODULE WITH DIDACTIC RESPONSIBILITY OF THE ENTIRE TRAINING ACTIVITY (ENABLING THE HEALTH PROFESSION OF ORTHOPEDIC TECHNICIAN) - Cycle: 1 - CFU: 6 Hours assigned: 24 hours from 01-11-2018 to date
* Teaching assignment in NURSING (QUALIFIED FOR THE HEALTH PROFESSION OF NURSES) - Cycle: 1 - Cfu: 1 Hours assigned: 12 hours from 01-11-2018 to today
* Teaching assignment in NURSING (QUALIFIED FOR THE HEALTH PROFESSION OF NURSES) - Cycle: 1 - Cfu: 1 Hours assigned: 12 hours from 01-11-2018 to today 2019/2020 - 41307 - SEMINARS - 2 module Medical oncology Degree course: 8483-ORTHOPEDIC TECHNIQUES - SEMINARS MODULE WITH EDUCATIONAL RESPONSIBILITY OF THE ENTIRE TRAINING ACTIVITY (ENABLING THE HEALTH PROFESSION OF ORTHOPEDIC TECHNICIAN) - Cycle: 1 - CFU: 6 Hours assigned: 24 hours
* 2019/2020/2021 - 75298 - SPECIALIST CLINICAL SCIENCES (C.I.) - ONCOLOGY - Degree course: 8476-PHYSIOTHERAPY (ENABLING THE HEALTH PROFESSION OF PHYSIOTHERAPIST) - Cycle: 1 - Cfu: 2 Hours assigned: 24 hours
* 2019/2020 - 76074 - MEDICINE 1 C.I. - MEDICAL ONCOLOGY - Degree course: 8479-PODOLOGY (ENABLING THE HEALTH PROFESSION OF PODIATRIST) - Cycle: 2 - CFU: 1 Hours assigned: 8 hours
* 2019/2020/2021 - 81477 - LOGICAL ONCO PATIENT MANAGEMENT(C.I.) - ONCO-HEMATOLOGY Degree course: 8474-NURSING (QUALIFIED IN THE NURSING HEALTH PROFESSION) - Cycle: 1 - Cfu: 2 Hours assigned: 24 hours
* 2019/2020/2021 - 39892 - CLINICAL INTERDISCIPLINARY SCIENCES (C.I.) - MEDICAL ONCOLOGY Degree course: 9079-TECHNIQUES OF MEDICAL RADIOLOGY, FOR IMAGES AND RADIOTHERAPY (ENABLING THE HEALTH PROFESSION OF MEDICALRADIOLOGY TECHNICIAN) - Cycle: 1 - Cfu: 1 Hours assigned: 12 hours
* 2019/2020/2021 - 39273 - CLINICAL SCIENCES OF THE MEDICAL-SPECIALIST AREA (C.I.) - ONCOLOGY AND PALLIATIVE CARE Degree course: 8473-NURSING (ENABLING THE HEALTH PROFESSION OF NURSE) - Cycle: 1 - Cfu: 1 Hours allocated: 12 hours
* 2019/2020/2021 - 39273 - CLINICAL SCIENCES OF THE MEDICAL-SPECIALIST AREA (C.I.) - ONCOLOGY AND PALLIATIVE CARE Degree course: 8474-NURSING (ENABLING THE HEALTH PROFESSION OF NURSE) - Cycle: 1 - Cfu: 1 Hours allocated: 12 hours

**INTEGRATIVE TEACHING AND STUDENT SERVICE ACTIVITIES, PARTICIPATION IN EXAM BOARDS AND ACADEMIC ROLES**

* A.Y. 1999/2000 and 2000/2001: she was Organizer of seminars in Oncology at the University of Bologna, with the coordination of Prof. G. Biasco, on the following topics: *"Stomach cancer", "Liver metastases from colon cancer", "The treatment of colon cancer", "Melanoma", "Prostate cancers", "Diagnostic techniques in Senology", "Radiotherapy and chemotherapy in rectum tumors".*
* A.Y. 2003/2004, 2004/2005 and 2005/2006: **he has carried out tutoring activities to** students of the Oncology Course as part of the Degree Course for Orthopedic Technicians and the Degree Course for Physiotherapists of the University of Bologna.
* **Responsible for the Internship of Oncology, Tutor and** Verbalizing Teacher in 2014-2015 at the SSD of Biasco Medical Oncology and in 2015-2016 of the Complex Operational Unit of Internal Oncology Medicine of continuity of care to date.
* **Tutorial and Supervisor** activities from the A.A. 2006/2007to date in the preparation of the Thesis of students of the Degree course of Medicine and Surgery, Nursing, Physiotherapy and the School of Specialization in Oncology, in total 13 Thesis in Medical Oncology.
* Tutorial activities **in the A.A. 2015/2016 to date** for Internship of **Medical Oncology as part of the Degree course of Medicine and Surgery.**
* **Tutorial activities of Research Fellows AA 2013-2014 and 2018-2019.**
* **Scientific coordinator for the University of Bologna of** the project "Distance Training" in Oncology (FADO) within the National Interuniversity Consortium for Bio-Oncology in the period January-February 2007 in collaboration with other including the University of Chieti, Ancona, Aquila
* Appointment as expert in the field for the teaching of medical **oncology (SSD MED/06) for the Cdl of Medicine and Surgery**
* **Appointed Commissioner for** the PhD in Oncology held on 15 December 2009 at the University of Ancona.
* **Appointment as Commissary** of examination for the assignment of an occasional work assignment for the needs of the CIRC (interdepartmental cancer research centre) on 1 March 2010.
* Appointment as admission examination commissioner at the School of Specialization of Oncology - University of Bologna held on 13/04/2010.
* Appointed Professor as Supervisor tutor of the PhD Student Dr. during the PhD in Oncology, Haematology and Pathology, 32nd Cycle of the University of Bologna from 01-11-2016 to today
* Appointed commissioner as secretary of the Admissions Competitions at the School of Oncology from 2010, 2011 and 2012.
* **Member of the Board of Department of Specialist, Diagnostic and Experimental Medicine** from July 2012 to November 2015
* **Member of the School Council (ex-Faculty) of Medicine and Surgery** of the University of Bologna from September 2012 to November 2015.
* **Member of the Board of Teachers of the School of Specialization in Medical Oncology of the University of Bologna with the function** of Secretary in the Councils since 2006.
* **Member of the Scientific Council of the First Level Master in Palliative Pain Care and the Master of Higher Education and Qualification in Palliative** Care, A.Y. 2014-2015.
* Appointed **Commissioner for the Italian language knowledge test of September 3, 2016 for foreign students for the A.A. 2016-2017.**
* Appointment as **Commissioner of the entrance test to the three-year degree courses of Physiotherapy for the A.A. 2016-2017** of September 13, 2016.
* Appointment as **Commissioner of the entrance test to the three-year degree courses of** **Orthopedic Techniques AA 2019-2020**
* Appointment to participate in the commission in the admission examination as secretary for the degree courses of **Medicine and Surgery and Dentistry and Dental Prosthesis for the A.A. 2017-2018,**5 September 2017 - Bologna.
* Appointment to participate **in the degree committee Degree Course of Nursing of Bologna, autumn session,**15 and 24 November 2017 - Bologna.
* **Head and Tutor of students in the internship of Medical Oncology for the School of Medicine and Surgery from the A.A. 2014-2015 to** date.
* Appointment **to participate in the committee in the** admission exam as secretary for the degree courses of Medicine and Surgery and Dentistry and Dental Prosthesis for the A.A. 2017-2018 from 05-09-2017 to 05-09-2017
* **Appointment to the Degree Committee of Infirmary** **as Vice President for the second session April 2018.**
* Appointment to the Degree Committee of Infirmary for the second session November 2018 university of Bologna - Campus of Faenza
* **Appointment as commissioner for the test at the admission competition to the Medicine & Surgery study** course, 13 November 2018 and also for AA 2019-2020.
* Member of the technical and pedagogical committee of the CDL of Medicine and Surgery
* **Educational coordinator of** the third channel C of the first semester of the fifth year of the Degree Course of Medicine and Surgery for AA 2018-2019.
* Appointment as **Vice-President of the Final Exams Commission in Nursing** on 10 and 18 April 2018.
* Appointment as Commissioner for the final exam of Degree and Qualification CDL Nursing, University of Bologna, November 2019, March 2020.
* Appointment as commissioner for the final exam of Degree and Qualification CDL Nursing, University of Bologna, Campus Faenza, November 2019.
* Supervisor professor for Dr. Durante S.'s PhD thesis in Oncology entitled "Identifications of new genetic alterations in pancreative ductal adenocarcinoma and precancerous lesions using Whole Genome Sequencing Oncoscan Array technology" March 2020.

**RESEARCH ACTIVITIES**

* **Internal student** at the Institute of Medical Clinic of the University of Bologna from December 1994, under the tutoring of Prof. G. Biasco, until obtaining a Degree in Medicine and Surgery in June 1997: in this period she attended the Laboratory of Gastrointestinal Histopathology, in the period of preparation of the thesis, carrying out studies on the mutagenicity of gastric juice through the Ames test, in collaboration with Prof. Patrizia Hrelia, Pharmacologist at the University of Bologna, scanning electron microscopy studies on gastric body duck biopsies, microbiological studies of the bacterial flora of gastric juice, under the supervision of Dr. G. Brandi;
* **Doctor specializing in Oncology from** November 1997, she continued to attend the Institute of Medical Clinic of the University of Bologna until September 1998, when she moved together with Prof. G. Biasco and her group at the Institute of Haematology and Medical Oncology L. and A. Seragnoli, Director Prof. S. Tura;
* Winner of **the "Ugo e Evaristo Stefanelli"** Scholarship in the A.A. 1998/99 at the University of Bologna for presenting the study on: " Evaluation of the *efficacy and toxicity of carboplatin and paclitaxel in the advanced NSCLC*" equal to £2,500,000;
* Winner of the Scholarship at the Health Company of **the Policlinico Sant'Orsola-Malpighi** of Bologna, activity carried out at the Institute of Haematology and Medical Oncology L. and A. Seragnoli from 26/11/01 to 25/11/02 to carry out research on "*Biomolecular targets of risk of colon and rectal* cancer " equal to £20,000,000;
* Winner of the PhD Scholarship in Experimental and Clinical Oncology XVII cycle with subsequent achievement of the title of PhD at the University of Modena and Reggio Emilia from 2002 to 2005.
* In the periods June 2003-December 2004, January 2004-April 2004, May 2004-December 2004, January 2005-June 2005 he carried out clinical and research activities, in particular on the Chemoprevention of colorectal cancer with Lipoic Acid and Folic Acid (MURST program ex-40%), at the Institute of Haematology and Medical Oncology – Sant'Orsola-Malpighi Polyclinic Company with Professional Free Contracts renewed from time to time.
* In the periods July 2005-December 2005, January 2006-April 2006, May 2006-September 2006 he carried out clinical and research activities within the multicenter study: " Randomized, double blind, placebo controlled, multicentric phase III trial to evaluate the efficacy and the safety of adding Bevacizumab to Gemcitabine and Erlotinib in patients with metastatic pancreatic cancer" at the Institute of Haematology and Medical Oncology – Sant'Orsola-Malpighi Polyclinic Company with Professional Free Contracts renewed from time to time.
* Award recognition as University Researcher of the Alma Mater Studiorum for the activities carried out by the Municipality of Vasto (CH).

**RELEVANCE IN THE SCIENTIFIC-DISCIPLINARY FIELD**

**Official call for reports at the following national scientific meetings:**

* She was selected to present in **the section Poster** "*Colorectal Gastro-intestinal Tumors*" the work "*New therapeutic* *strategies* *in advanced* *colorectal cancer: our clinical experience*" at the **3rd National Congress of Medical Oncology,** held in Naples from4 to 7 November **2001;** published in the Journal Annals of Oncology, 2001; Vol. 12, suppl. IV: p. 8 (Abstract A21); P. Mordenti, **MC Di Marco**, MA Pantaleo, E. Gallerani, G. Brandi, M. By Battista, G. Biasco. "The Folfox-4 regimen: a mono institutional experience in advanced colo-rectal cancer (ACC)".
* Called to **present** a report as part of the internship "***Head-neck tumors: nosological classification*",** held in Bologna on November 23, **2005;**
* **Speaker** at **the Scientific Meeting "Pancreatic Cancer: A Clinical Update"** on June 16, **2006** on the topic: "The new agents".
* Selected to present in the **Poster** Section in **2006** at the **World Congress on Gastrointestinal cancer**, Barcellona between 28/06/06 and 01/07/06, “Effect of folate and alpha lipoic acid supplementation on rectal mucosal cells kinetics.”
* **Speaker** at the Conference of 6-7 October **2006,** held in Matera, as part of the Congress "Pancreatic tumors and **acute pancreatitis",** with a report entitled "Target *therapies*".
* **Relator** for **Mediterranean School of Oncology** to the “Highlights in management of gastrointestinal cancer”, 11-12 April **2008**, Roma, with relation titled “*Progresses in the treatment of the pancreatic cancer*”.
* Called to present a **Poster and oral communication at** the 32nd National Congress of the Italian Association for the Study of the Pancreas **(A.I.S.P.),** Montecatini Terme, 2-4 October **2008.**
* Call for oral **communication at** the **33rd National Congress of the Italian Association for the Study of the Pancreas (A.I.S.P), Rozzano, 15-17 October 2009.**
* Invited to relate in quality of Professor at the **Mediterranean School of Oncology, “Highlights in the Management of Gastrointestinal cancer”** with relation titled: “**Pathobiology and treatment of pancreatic cancer”, Roma May 21-22, 2010.**
* **Selected as Referee in April 2010 in the scientific publication Journal of pancreas (JOP) as expert opinion in pancreatic cancer.**
* **Speaker at the AIOM Bologna Congress 2011 with a report entitled: " Oncology training in the** control of symptoms" in place of Prof. G. Biasco.
* **Referee** of pancreas **and** **neoplasm magazine** since 2012.
* Speaker at the Congress II Meeting of Live Surgery in hepato-bilio-pancreatic surgery, Bologna, 4-5 April 2013.
* **Call as moderator at the 37th National Congress of the Italian Association for the Study of the Pancreas (A.I.S.P), Bologna 19-21 September 2013**
* **Invitation as Expert Delegate representing Italy to the Pancreatic cancer forum Madrid 29-30 November, 2013.**
* **Invitation as Expert Delegate to the** Pancreatic Cancer Forum 2014, Munich, 28-29 November 2014.
* Speaker at the II Women Workshop "The new frontiers of nanotechnology in solid tumors", Peschiera del Garda, 30 October 2015.
* Speaker at meet the expert "pancreatic cancer" with report entitled "Metastatic disease in the fragile patient", Ferrara, 22 June 2016.
* Speaker at the MGB I Meeting of Gastroenterology in Bologna: New frontiers of ecoendoscopy in biliopancreatic pathology: a multidisciplinary approach, 12 September 2016.
* Invited to participate in the Editorial Board of the journal Integrative Cancer Biology & Research, September 23, 2016.
* Medical oncology advisory board on the use of irreversible electroporation for the treatment of pancreatic adenocarcinoma, Roma, 27 October 2016.
* Invitation as esparto delegate to the Central European Cooperative Oncology Group (CECOG), Pancreatic Cancer Academy, Vienna, 10-12 November 2016
* Lecturer at the conference "Pancreatic cancer: new challenges, new hopes?", 31 March 2017, Bologna
* Speaker at the Workshop "Pancreatic cancer and precancerosis, Special clinical cases", 1 April 2017, Bologna.
* Speaker at the Conference World Pancreatic Cancer Day, 16 November 2017, Bologna.
* **Member of the Italian Pancreatic Study Association (AISP) from 2006 to the present.**
* **Member of the Italian Association of Medical Oncologists from 2009 (AIOM) to the present.**
* **Member of the European Pancreatic Club (EPC) from 2014 to the present.**
* **Member of International Association of Pancreatology from 2018.**
* **Member of the Interdepartmental Centre for The Study and Research on Pancreatic Neoplasms DIMEC-DIMES and** **member of the Scientific Committee** from **2016 to the present.**
* **Speaker at the Conference "Pancreatic tumors from epidemiology to new therapies"** in Chieti on April 27, 2018.
* **Relator at** Interactive Web Conference Pancreatic Cancer, AIR NAb-paclitaxel interactive Report, in Milan 8 June 2018 in web conference from Aemilia Hotel di Bologna.
* **Participation in the Advisory Board** "Pancreatic cancer: optimization of the therapeutic path in a multidisciplinary perspective", 11 December 2018, Milan.
* Poster presentation EPC 2015, Toledo, titled "DISCOVERY OF NEW POTENTIALLY ACTIONABLE MUTATIONS IN PANCREATIC DUCTAL ADENOCARCINOMA BY NEXT GENERATION SEQUENCING"
* Poster presentation at Congress EPC 2017 as coordinator of research titled "TERC AND MYC COPY NUMBER GAIN AS POWERFUL GENETIC MARKERS FOR INTRADUCTAL PAPILLARY NEOPLASMS OF THE PANCREAS", Budapest
* Poster presentation at Congress EPC 2018 in Berlin as coordinator of research group named "Mutational burden of resectable pancreatic cancer by whole-transcriptome and whole-exome sequencing could predict a poor prognosis"
* Coordinator of the research group on the theme "Searching for **novel multimodal treatments in oligometastatic pancreatic adenocarcinoma: a case report.** " And poster presenter at EPC 2019 in Bergen (Norway) June 26-29, 2019.
* Speaker at the nanomedicine conference Nutrition Surgery "The synergistic approach to cancer patients", Rome 2 July 2019.
* Speaker at the 30th meeting of Clinical Oncology Genetics, Bologna 11 December 2019, entitled "Pancreatic carcinoma: epidemiology, prognosis and therapy.

**PARTICIPATION IN SCIENTIFIC AND EDUCATIONAL INITIATIVES AT NATIONAL AND INTERNATIONAL LEVEL**

* 1998: she was a member of the **Local Organizing Committee** of the International Conference "*Gastric Cancer from chemoprevention to chemotherapy*" held in Bologna from 16 to 17 April;
* 1998: she was a member of the Editorial **Committee,** under the direction of Prof. G. Biasco, of the periodical "*Bullettino delle Scienze Mediche*", Organ of the Society **and Medical-Surgical School of Bologna** (January and December);
* 2004: she was nominated for the Scientific **Secretary** of the Scientific **Meeting** "*Oral Chemotherapy in Oncology*", held in Bologna on May 4;
* 2005: **Internship Coordinator and Rapporteur** "*Brain tumors, melanoma, head-neck tumors*" held in Bologna between 21 and 23 November 2005;
* 2006: **Scientific Secretariat and Rapporteur** of the scientific meeting "Pancreatic cancer: a clinical update". Bologna, 16 June 2006;
* 2006: **Coordinator of the internship** "Support therapies in Oncology", Bologna 26-28 June.
* 2012: **Member of the Organizing Committee of** the XXXVI AISP Congress (Italian Association of Pancreas Studio) Bologna 4-6 October 2012.
* 2017: **Member of the Scientific and Organizational Committee of the Congress "Pancreatic Cancer: New Challenges, New Hopes?",** 31 March 2017, Bologna.
* **Member of the study and research centre on diseases of the pancreas CSR of DIMEC/DIMES** in collaboration with the operational units of Surgery Prof. Minni, Nuclear Medicine and Gastroenterology from 2015 to the end.

**PARTICIPATION AND RESPONSIBILITY IN NATIONAL AND INTERNATIONAL RESEARCH PROJECTS ELIGIBLE FOR FUNDING**

* Scientific coordination of the main research unit RU1 within the Study "Whole-transcriptome paired-end sequencing in pancreatic cancer and precursor lesions: from early detection to therapeutic implication". Research Call Region-University, Area I - Young Researchers Call - Alessandro Liberati 2013. Financing of €198,000. 01-01-2013 to 01-10-2016
* He participated as a member of the group of teachers, coordinated by Prof. Giovanni Martinelli, applicants for the Alma Idea Equipment 2017 Call, which was first and obtained funding amounting to € 247,000, for the following equipment:
  + CELLTRACKS®AUTOPREP® System: system that allows to standardize and optimize the process of enrichment of rare cells; includes automatic sample preparation with immuno-magnetic methodology
  + CELLTRACKS ANALYZER II: Semi-automatic system based on fluorescence optics to count selected rare cells. · REMOTE REVIEW WORKSTATION
  + DEPArray NxT: system for the isolation of rare cells, with purity of 100% (up to 1 single cell). The system allows up to 96 recoveries. From a sample of 10,000 cells, individual cells can be recovered in 1 hour.
  + Remote Multitask DEPArrayTM NxT Control Workstation: software that allows remote analysis of the data obtained (even while the tool is analysing other samples).
  + Cytofluorimeter CytoFLEX System B5-R3-V5 from 09-05-2017 to today
* Winner of the funding of the basic research activities by the MIUR in 2017 from 01-07-2017 to 01-07-2017

**RESEARCH AND SCIENTIFIC PRODUCTION ACTIVITIES**

**VRA evaluation of** **the candidate AA in 2017-2018-2019-2020.**

COORDINATION AND PARTICIPATION IN RESEARCH PROJECTS AND CLINICAL TRAILS AS PRIMARY INVESTIGATORS AND CO-INVESTIGATORS

Coordination and participation in various research **projects (ex** 40% and ex 60%) funded by the MIUR, of which the year, title of the research and job carried out are reported:

* **RFO project ex 60%** presented **in 2001** and accepted: "Biological and ultrastructural alterations, and risk of duodenum cancer in family adenomatous polyposis" with the task of Clinical Analysis;
* **PRIN project** presented on 19 April  **2002** and accepted: "Effect of the administration of antioxidants and folic acid on the cell proliferation of epithelial cells of the rectum in subjects at risk of colon cancer" with the task of Patient Selection and Analysis of Cellular Kinetics, periodic reporting and closure of the project; this project was the subject of the PhD **thesis** obtained in 2005, subsequently **presented in the poster session of the 2006 World Congress on Gastrointestinal cancer, Barcelona** and published in the journal **Annals of Oncology:**  **MC Di Marco,**R. By Cecilia, M. By Battista, E. Palmerini, E. Derenzini, R. Poggi, S. Fanello, M. Astorino, G. Biasco. "Effect of folate and alphalipoic acid supplementation on rectal mucosal cells kinetics." Poster 153, Suppl. 6
* **RFO project ex 60%** presented on 14 May **2003** and accepted: "Biological prognostic factors of colon cancer and therapeutic implications" with data processing task;
* Project **RFO ex 60% 2008**and accepted: “Effect of serine proteases inhibitor gabexate mesylate (GM) on the activity of gemcitabine (G) in cell lines of pancreatic cancer”.
* **PRIN project 2009** accepted in 2011, "Integrated genomic analysis of the response to neoadjuvant chemo-radiotherapy in the treatment of resectable and locally advanced pancreatic adenocarcinoma" in collaboration with General Surgery Prof. Minni, Head of Mod. B, and the Universities of Pisa (coordinator Prof. Boggi, mod. A), Florence and Turin, has played a direct role as a component in the drafting of the project, in the randomization of patients and in the **collection of biopsies;** this project is in line with the scientific and research path of the activity of myself.
* **RFO project ex 60%**   **of 2011**: "Isolation of cancer stem cells from human pancreatic tumour tissue", with the task of drafting the project and coordinating and organizing it.
* Project **Young Researchers** winner of **the Call Andrea Liberati Uniregione** in December **2013,** "Wholetrascriptome paired end sequencing in pancreatic cancer and precursor lesions: from early detection to therapeutic implication" with the task of head and **coordinator** of the Main Research Unit.
* Recognition of af-funding of basic research activities by the MIUR in 2017.
* He participated as a member of the group of teachers, coordinated by Prof. Giovanni Martinelli, applicants **for the Alma Idea Equipment 2017**Call, which was first and obtained funding amounting to € 247,000, for the following equipment:
  + CELLTRACKS®AUTOPREP® System: is theme that allows to standardize and optimize the process of enrichment of rare cells; includes the automatic preparation of the sample with immuno-magnetic methodology
  + CELLTRACKS ANALYZER II:semi-automatic is theme based on fluorescence optics to count selected rare cells. · REMOTE REVIEW WORKSTATION
  + DEPArray NxT: Shythema for the isolation of rare cells, with purity of 100% (up to 1 single cell). The system allows up to 96 recoveries. From a sample of 10,000 cells, individual cells can be recovered in 1 hour.
  + Remote Multitask DEPArrayTM NxT Control Workstation: software that allows remote analysis of the obtained data (even while the tool is analysing other samples).
  + Citofluorimetro CytoFLEX System B5-R3-V5
* Component of research unit B, extension of project **PRIN 2017** “Dissection of the cross-talk between cancer cells and cancer-associated fibroblasts by next generation sequencing in resectable pancreatic adenocarcinoma to identify new prognostic markers or potentially actionable targets”, in collaboration with Pisa University, Unity of principal research, PI Prof. Ugo Boggi, and Verona.

He has also participated in several spontaneous **and multicenter controlled national** and international clinical trials as *primary investigator* *or co-investigator,* making personal requests to the local ethics committee for their acceptance, listed below:

1. Coinvestigator in the "Phase II study with Carboplatin and Paclitaxel in patients with advanced NSCLC", 1998;
2. Coinvestigator in the Multicenter Study: “Subcutaneous IL-II + NSAIDs treatment in advanced NSCLC patients”, 1999;
3. Coinvestigator in the Multicenter Study: “RP64174A-V-307: Multicenter, Phase III, Open Label, Randomized Trial Comparing CPT-11 in Combination with a 5-FU/FA Infusional Regimen to the same 5-FU/FA Infusional Regimen Alone as Adjuvant Treatment of Stage II and III Colon Cancer”;
4. Coinvestigator in the Multicenter Study phase II: “Temozolomide and interferon-alpha in metastatic melanoma: a phase II study on the Italian Melanoma Intergroup”, presented and accepted from etic committee on 26 May 2000;
5. Coinvestigator in the Multicenter Study: “Double-Blind Clinical Study to Compare Single IV Doses of Palonosetron, 0.25 mg or 0.75 mg, and Ondansetron, 32 mg IV, in the Prevention of Moderately Emetogenic Chemotherapy-Induced Nausea and Vomiting”, prot. N° PALO-99-03, presented and accepted from etic committee on 23 August 2000;
6. Coinvestigator in the Multicenter Study: “Double-Blind Clinical Study to Compare Single IV Doses of Palonosetron, 0.25 mg or 0.75 mg, and Ondansetron, 32 mg IV, in the Prevention of Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting”, prot. N° PALO-99-05, presented and accepted from etic committee on 23 August 2000;
7. Coinvestigator in the Multicenter Study: “A multicenter, Open-Label study to assess the Safety and Efficacy of IV Palonosetron for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Repeated Chemotherapy Cycles”, prot. N° PALO-99-06, presented and accepted from etic committee on 23 August 2000;
8. Coinvestigator in the Spontaneous Study: "Effect of the administration of antioxidants and folic acid on the cell proliferation of epithelial cells of the rectum in subjects at risk of colon cancer", (MIUR program ex 40%), presented and accepted by the Ethics Committee in 2002;
9. Coinvestigator in the Pilot Study for the verification of the chemo preventive effect in subjects at risk of colon cancer, presented and accepted by the Ethics Committee in 2002;
10. Coinvestigator in multicentric study: “Phase III, Randomized Double-Blind, Placebo-Controlled Study of SU011248 in the Treatment of Patients with Imatimib Mesylate (Gleevec, Glivec)-Resistant or Intolerant Malignant Gastrointestinal Stromal Tumour”;
11. Coinvestigator in the Multicenter Study: "Epidemiology of Emesis Treatments in Oncology", presented and accepted by the Ethics Committee in January 2004;
12. Coinvestigator in the randomized, open-label, phase III, multicenter, adjuvant chemotherapy for radically operated stomach or oesophagus oyster adenocarcinoma adenocarcinoma: comparison of sequential treatment (CPT-11 + 5FU/LV is TXT + CDDP) vs. a 5-FU/LV regimen, IRFNEGR III protocol, 2004, 003, presented and accepted by the Ethics Committee in January 2005;
13. Coinvestigator in international multicentric study: “Randomized, double blind, placebo controlled, multicentric phase III trial to evaluate the efficacy and the safety of adding Bevacizumab to Gemcitabine and Erlotinib in patients with metastatic pancreatic cancer”, accepted from etic committee on 26 July 2005;
14. Coinvestigator in international multicentric study: “A phase IIIB study of Tarceva (Erlotinib) in patients with locally advanced, unresectable or metastatic pancreatic cancer”, accepted from etic committee on 20 March 2007;
15. Coinvestigator in the Randomized Prospective Study on Neoadjuvant Chemoradiotherapy Associated with Surgery vs. Surgery in Patients With Resectable Pancreatic Adenocarcinoma (prot. EUDRACT 2007-000557-611), accepted by the ethics committee in March 2007, in collaboration with the NEOPAN Multidisciplinary Group (Surgery, Radiotherapy, Internal Medicine) which deals with pancreatic cancer within the Policlinico Sant'Orsola-Malpighi; (public no. 14-17)
16. Coinvestigator in the Spontaneous Study: "Hyperexpression of tissue transglutaminasis and implications in multidrug resistance in pancreatic cancer", December 2007;
17. Coinvestigator in international multicentric study: “A randomized, double blind phase III study og Gemcitabine plus AG-013736 versus Gemcitabine plus placebo for the first line treatment of patients with locally advanced unresectable or metastatic pancreatic cancer”, accepted from etic committee on 18 December 2007;
18. Coinvestigator in the National Multicenter Study promoted by the GISCAD Foundation for Tumour Research coordinated by the Medical Oncology of the University of Ancona (Prof. S. Cascinu): "Phase II study randomized with Gemcitabine/Cisplatin with or without Sorafenib to evaluate the effectiveness and safety of treatment in patients with locally advanced or metastatic pancreatic tumors. Studio MAPS. Accepted by the Ethics Committee on March 4, 2008;
19. Coinvestigator in international multicentric study “A phase II randomized, open-label, multicenter study comparing CO-101-001 with Gemcitabine as first-line therapy in patients with metastatic pancreatic adenocarcinoma”, May 2010, to what participate only 7 Italian Centre, Italian coordinator General Surgery University of Verona (Prof. Bassi);
20. **Primary investigator** in the National Multicenter Study called PACT – 15 (Pancreatic Cancer Trial) entitled "Randomized phase II-III study of perioperative or adjuvant chemotherapy in patients suffering from resectable pancreas adenocarcinoma", May 2010, coordinator centre for S. Raffaele Hospital - University of Milan (Dr.M. Reni).
21. **Primary investigator** in the international Multicentric study “A Randomised, Open-Label, Proof-of-Concept, Phase II Trial Comparing Gemcitabine with and without IMM-101 in Advanced Pancreatic Cancer”, protocol IMM-101-002.
22. Coinvestigator in the Ancillar Study on the gene expression profile (genotyping) of patients with operable pancreas adenocarcinoma amendment of the "randomized prospective study on neoadjuvant chemoradiotherapy associated with surgery vs. surgery in patients with reductable pancreatic adenocarcinoma" EUDRACT Code 2007-000557-61.
23. Coinvestigator in the Study on the profile of gene expression and genotyping of patients suffering from adenocarcinoma of the pancreas not operable (locally advanced and metastatic) GENOPAN of 21/08/2012, accepted by the Ethics Committee.
24. **Responsible experimenter** in the study "Use of RECIST and CHOI criteria in the evaluation of radiological response in patients suffering from non-reductive pancreatic heteroplasia" Prot. ONCO-2013-RECIST/CHOI, July 2013.
25. **Experimenter Head** of Italian Multicenter Randomized Phase III Study comparing the combination of 5-fluoruracile/folinic acid, oxaliplatin and irinotecan (FOLFOXIRI) towards Gemcitabine in the adjuvant treatment of pancreatic cancer - Study Italian Pancreas GIP2 Group in collaboration with the University of Pisa, 2015.
26. **Responsible Experimenter** to the Observational Study "A prospective evaluation of pancreatic cyst surveillance, based on the European experts consensus statement on cystic tumours of the pancreas" - Prot. Pacyfic, in collaboration with l'U.O. Chirurgia Generale - Minni - Erasmus MC - University; Medical Center Rotterdam, 2015.
27. Prospective, multicenter, double-randomized, double-blind, 2 parallel groups, phase III to compare the efficacy and safety of masitinib in combination with gemcitabine as a first-line therapy, versus Gemcitabine in combination with placebo, followed by second-line treatment with masitinib in combination with folfiri 3 versus placebo in combination with folfiri 3, in the treatment of patients suffering from locally available or metastatic pancreatic cancer, 2015.
28. **Investigator responsible** IQ-BTP Impact Study in the population with chronic pain, 2015. Closed in December 2019.
29. Participation in quality of coinvestigator to the Study APACT A PHASE 3, MULTICENTER, OPEN-LABEL, RANDOMIZED STUDY OF nab®-PACLITAXEL PLUS GEMCITABINE VERSUS GEMCITABINE ALONE AS ADJUVANT THERAPY IN SUBJECTS WITH SURGICALLY RESECTED PANCREATIC ADENOCARCINOMA, 2015.
30. **Responsible Experimenter** of Study "A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GS 5745 Combined with FOLFOX6 as First Line Treatment in Patients with Advanced Gastric or Gastroesophageal Junction Adenocarcinoma", 2016.
31. **Responsible Experimenter** (PI) "Multicenter phase 3 study, randomized, double-blind, placebo-controlled on olaparib maintenance monotherapy in patients with metastatic pancreatic carcinoma with gBRCA mutation who did not show progression during platinum-based first-line chemotherapy", activated in December 2017 and still ongoing.
32. **Responsible Experimenter** (PI) "Guideline Application in Real world: multi-Institutional Based survey of Adjuvant and first Line pancreatic Ductal adenocarcinoma treatment in Italy” - Prot. GARIBALDI - Promoted to Italian Oncology Medical Association (AIOM), activated in February 2018 and today in course.
33. Coinvestigator in collaboration with the Operating Unit of Radiotherapy Prof. A.G. Morganti, University of Bologna, for the "Interventional study without medicine, multicenter in patients suffering from locally advanced adenocarcinoma of pancreas: stereotactic radiotherapy." (IRENE-1: Improving Resectability in pancreatic Neoplasm).

The research activity and the related scientific production since the date of recruitment has been mainly focused in the field of Clinical Oncology, in particular in Chemo-prevention and Gastrointestinal Oncology, with predominant interest in the treatment of pancreatic cancer, as demonstrated by the latest refresher forums and participation in courses or congresses as speaker or organizer of scientific meetings, such as the AISP Congress. This activity has allowed participation in several international and national trials, in addition to the collaboration with multidisciplinary working groups (surgery, pathological anatomy, radiology, internal medicine), not only of the University of Bologna, but of other leading Italian university centers in the treatment of the aforementioned pathology **(University of Verona, Milan, Pisa, Ancona, Rotterdam, Columbia University).**

**RESEARCH AREAS IN ONCOLOGY**

**Stomach cancer**

I started experimental research during the period of the degree thesis entitled "Hypochloridria and carcinogenesis of the stomach", this research continued in the clinical field with the participation as covestigator in the randomized open-label, phase III, multicenter study, adjuvant chemotherapy for radically operated stomach adenocarcinoma or esophagical junction: comparison of sequential treatment (CPT-11 + 5FU/L V is TXT + CDDP) vs. a 5-FU/LV regimen. and below at FOLFOX6 as First Line Treatment in Patients with Advanced Gastric or Gastroesophageal Junction Adenocarcinoma.

**Lung cancer**

The Phase II study with carboplatin and paclitaxel aimed at treating patients with NSCLC was carried out. (Publication "**Carboplatin (CBDCA) and Paclitaxel (TAX) in advanced non small cell lung cancer (NSCLC): preliminary results".**

**Support therapies: treatment of emesis**

Three studies were therefore involved in 3 studies in order to verify the efficacy of Palonosetron (0.25 or 0.75 mg) in the prevention of nausea and vomiting induced by moderately or highly hematogenic chemotherapy treatment, compared with a single dose of Ondansetron (32 mg) by endovenous. Palonosetron, in fact, administered both intravenously and orally, has been shown to have a half-life of about 40 hours in man. An epidemiological study was also carried out to describe the therapeutic practices for the control of chemotherapy-induced emesis and to detect what therapeutic indications are given to patients for home management of the problem.

**Biological, ultrastructural alterations and risk of duodenum cancer in FAPs**

Neoplastic alterations of the mucous membrane in patients with FAP are preceded by biological abnormalities. Alterations of the cellular proliferation kinetics of the duodenal mucosa are present in all patients with FAP. In those where dysplasia of the mucous membrane is observed, such alterations are more marked. Kinetic alterations are likely to be related to a cell maturation defect for which research has been undertaken with 3 objectives:

1. verification of the stability of cellular kinetics of the duodenal mucosa, already demonstrated in subjects with FAP;
2. verification of the predictive value of risk of the appearance of adenomas in subjects with FAP and cytotoproliferative alterations;
3. histological and ultrastructural analysis of duodenal biopsies of the same patients in search of a correlation between structure and proliferative anomalies of the mucous membrane.

(Ref. **Research project ex 60% 2001**, previously listed).

**Chemoprevention of cancer**

Several studies have indicated that abnormalities of cell proliferation of the colorectal mucosa are associated with the risk of developing neoplasm. It has been shown that specific dietary factors or certain drugs can inhibit the induction and progression of different types of cancer, including colorectal cancer. Among these compounds, some antioxidants and folic acid appear to have real effects on inhibition of the tumor progression process and on the expression of neoplasm after exposure to carcinogens. On the basis of these observations, 2 studies were carried out, one funded by MURST and one by Montedison, to verify the effect of lipoic acid and folic acid as food additives in the prevention of colocancer no.

(Publications:

**Chemoprevention of colorectal cancer**, THE INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS

**Folate and prevention of colorectal cancer in ulcerative colitis.** EUROPEAN JOURNAL OF CANCER PREVENTION)

**Colon cancer**

For years 5-fluoruracile has been the cornerstone of various therapeutic regimes, clinical research fortunately in recent years has made available new drugs characterized by significant activity; among these new molecules:

* oxaliplatin has played a particularly important role in the mechanism of action that is absolutely innovative and different from fluoropyriimidines; however, the favourable toxicological profile is burdened in clinical experience by the unpredictable appearance of hypersensitivity reactions.
* the Irinotecan has been shown to significantly increase overall survival.

On the basis of these premises, a retrospective study was carried out with the aim of examining the clinical impact of the rapid change in therapeutic strategies of advanced colon cancer. This study, the subject of the Specialty Thesis, was aimed at evaluating the effectiveness and survival in patients suffering from advanced colon cancer subjected to various therapeutic lines containing the aforementioned drugs. Subject of severalpublished actionson the list and subject of participation as covestigator in the multicenter study "RP64174A-V-307: Multicenter, Phase III, Open Label, Randomized Trial Comparing CPT-11 in Combination with a 5-FU/FA Infusional Regimen to the same 5-FU/FA Infusional Regimen Alone as Adjuvant Treatment of Stage II and III Colon Cancer".

**Oral fluoropyimidine**

In recent years, the therapeutic landscape in Oncology has expanded with the advent of oral fluoropyriimidine. The advantages derived from oral administration, compared to intravenous administration, are related to less toxicity and less hospitalization time. The most studied drug in this category is Capecitabine, followed by UFT. In recent years, therefore, the interest of clinical activity has also been directed at patientstreated with these drugs. (Publication **Is oral therapy a real plus?** TUMOR SUPPLEMENTS)

**Adjuvant colon cancer**

The study of patients operated on for colon cancer at DUKES' B and C stage in treatment with fluorofolates according to the De Gramont and CPT-11 scheme has now been closed and data are being *collected for interim analysis* at 2 years and 6 months of follow-up. STUDY PETACC3.

**Advanced melanoma**

Temozolomide is a drug that does not require liver metabolism, unlike dacarbazine, an active agent on melanoma. Therefore the advantage of this drug over dacarbazine lies in the exclusion of intercompatint pharmacokinetics as well as in the ability to cross the blood brain barrier. This substance was an alternative to dacarbazine in the treatment of metastatic**melanoma.** The study carried out was to evaluate the response and safety of Temozolomide in combination with interferon alpha (drug indicated in adjuvant treatment in patients at high risk of systemic melanoma recurrence) at the forefront of the treatment of patients with metastatic melanoma FROM THIS Multicenter STUDY of which I PERSONALLY PARTICIPATED IN RANDOMIZATION as well as PATIENT MONITORING and data collection and resulted in the publication in the journal Melanoma Research **work** that had many citations. (Publication **Temozolomide and interferon-alpha in metastatic melanoma: a phase II study on the Italian Melanoma Intergroup.** MELANOMA RESEARCH)

**GIST (gastrointestinal stromal tumors)**

Since the year 2000, the effectiveness of targeted molecular therapy with Imatinib Mesilate (Glivec) has been demonstrated. However, a significant proportion of late-stage GIST patients develop resistance during treatment. For this reason, a study has been undertaken with SU011248, a molecule capable of inhibiting the activity of receptors for VEGF, PDGF as well as Kit. Thus, in principle, the treatment appears to be able to perform antitumor activity in Imatinib-resistant GIST thanks to potentially antiangiogenic activity. The study aims to compare time to progression related to the administration of SU011248 associated with the best support therapy towards that determined by placebo administration and better support therapy in patients with late-stage GIST resistant or intolerant to Imatinib Mesilate therapy.

**Prognostic factors of colon cancer**

The refinement of immunohistochemical and biomolecular techniques today offers the possibility to create an individual prognostic profile to be used in terms of surveillance and personalized treatment. A research study has therefore been undertaken to identify the biomorphological expression of colorectal cancer, in particular the rate of cell proliferation, the expression of cyclo-oxygenase II and the epidermal growth factor (EGF) with a view to the implementation of a therapy program with specific biological agents**(Ref. Research project ex60% 2003,**previously listed).

**Pancreatic cancer**

The limited success of chemotherapy in patients with advanced pancreatic cancer has encouraged the search for new agents. In fact, clinical data are emerging to support the activity of VEGF and EGFR inhibitors in the treatment of several solid tumors, including pancreatic cancer. For example, a relatively high incidence was found (30-50%) of an "overexpression" of EGFR in patients with pancreatic carcinoma compared to healthy controls and there is evidence to support the role of this receptor in the tumor characteristics of mitogenesis, metastases, angiogenesis and resistance to cytotoxic therapies. A randomized double-blind multicenter study, placebo phase III controls, was therefore adhered to in order to assess the efficacy and tolerability of Bevacizumab (anti-VEGF) associated with Gemcitabine and Erlotinib (anti-EGFR) compared to placebo associated with Gemcitabine and Erlotinib in patients with metastatic pancreatic cancer. This study was accepted by the Ethics Committee on 26/07/2005. From the research activity and from the experience gained on this pathology both in patients operated and in patients at an advanced stage, who have undergone multimodal treatment regimen: adjuvant therapy, chemoradioterwith piousneoadjuvant, second-line therapies in advanced disease in recent years have resulted from extensive publications (reviews, case reports) and abstracts of congresses such as ASCO meetings, AISP and AIOM that have been published *in journals* such as JCO, Annals of Oncology, JOP, Oncology report, Oncology letters, Pancreas, Case report of gastroenterology (subject to numerous citations also in journals with a high scientific impact eg. MR NEJM). (Publication  **Metastatic pancreatic cancer: is gemcitabine still the best standard treatment?** (Review). ONCOLOGY REPORTS)

**PROJECT EX 60 % (RFO) 2008**

Pancreatic cancer is still the fourth leading cause of cancer death in the world: in the US, the estimated incidence in 2008 was 37,680 new cases with 34,290 deaths. The natural history of this neoplasm is characterized by a particularly inaustic prognosis: global survival is around 1% at 5 years and only 20-30% of patients with metastatic disease survive more than 1 year. Due to its intrinsic characteristics, such as the appearance of nonspecific symptoms only late, pancreatic carcinoma is metastatic to diagnosis in 30-50% of cases.

Metastatic dissemination is the culmination of a complex process that evolves over a long period, and that is based on necessary stages such as proteolysis, the acquisition of motility and adhesion capacity by cancer cells. In particular, we know that proteolytic modification of the extracellular matrix is the main component of the neoplastic invasion process: among the enzymes involved are matrix metalloproteinase (MMP) and Serino-proteases such as associated tumor trypsinogen (TAT) and urokinase (uPA). The latter is responsible for the conversion of plasminogen to plasmin, which in turn can act by directly degrading the proteins of the matrix or go to activate the pro-MMP.

As in other neoplasms, there is also a hyper expression of proteolytic enzymes such as u-PA in the adenocarcinoma of the pancreas, alongside the down-regulation of its inhibitory factor, PAI-1. Such alterations correlate with an increase in metastatic potential and therefore with a reduction in survival. Equally in tumor tissue there is over-expression of TGF-β, a growth factor involved in the acquisition of invasive and metastatic characteristics by cancer cells. In particular, TGF-β1 up-regulates the cellular expression of MMP and u-PA in an autocrine manner; Plasmin, obtained from the conversion of plasminogen by u-PA in turn causes the activation of the latent form of TGF-β1, thus creating a vicious circle promoting metastatization. In addition, studies on pancreatic cancer cell lines have shown that TGF-β1 induces an increase in VEGF production thus causing a powerful angiogenic stimulus. The use of Gabesato Mesilato (GM), a protease inhibitor used in the prophylaxis of post-ERCP acute pancreatine, has been shown to be effective in achieving a reduction in u-PA and TAT levels in pancreatic cancer cell lines, thus also reducing the activation of TGF-1.

Therefore, a protocol has been activated for the use of this drug in pancreatic adenocarcinoma to reduce and block the process of cellular metastatization. This process was achieved on the one hand by direct interference in the proteolytic invasion processes involved, and on the other by blocking the angiogenic stimulus on cell lines of pancreatic cancer. From these studies it was possible to publish such data during National and International Congresses (ASCO, AISP and EPC) for which an AISP award was won in favor of a younger researcher as a participant in the project.

**PROJECT PRIN 2009**

Surgical therapy of pancreatic cancer has so far been the only treatment capable of allowing a long-term chance of survival in the adenocarcinoma of the pancreas, but it is only possible in 10% of cases. In addition, the marked and early tropism of neoplastic cells for the vascular and perineural components of peripancreatic tissues makes it very difficult to obtain a resection with neoplasm-free margins, so that about 80% of cases experience local or remote recurrence. In order to reduce R1 pancreatic resections, the share of local relapses and, as a result, increase long-term survival, we began a randomized prospective clinical trial on neoadjuvant chemotherapy associated with surgery versus surgery in patients with reductive pancreatic adenocarcinoma (EUDRACT 2007-000557-611). The primary objective of the study is to verify whether the rate of surgical resections R0 is significantly higher in the group treated with neoadjuvant chemoradiotherapy than that treated with surgery alone. Ancillary evaluations are the evaluation of the toxicity of neoadjuvant chemoradiotherapy, the difference in pTNM stage, mortality and postoperative morbidity between the group treated with neoadjuvant therapy and the untraceable one. The second objective of the study is to identify the genetic markers that characterize *good responder tumors to* neoadjuvant treatment, in order to allow a better identification of patients eligible for therapy, as well as to develop combined therapies that selectively interfere with the chemo intrinsic resistance of the tumor, with a view to tailored-therapy specific to each patient. At this stage of the study, patients with locally advanced cancer will also be involved, therefore not eligible for inclusion in the EUDRACT 2007-000557-611 protocol, but in fact subjected to the same chemo-radiotherapy treatment as enlisted. The search for predictive response markers will be based on the integration of genetic, genomic and molecular analyses, evaluating on the same bioptic sampling the profile of gene expression and miRNA, the analysis of high-resolution copy numbers, and the mutational analysis of the main oncogenes mutated in tumors. The integration of this information with clinical data of sensitivity or resistance to neoadjuvant treatment will allow to identify molecular predictors to be validated on independent case studies, and to be studied at a functional level in in vitro models of sensitivity to treatment (in collaboration with the other Operational Units of General Surgery Prof. Minniresponsabile Research Unit). Therefore, prin 2009 funding was obtained (accepted in July 2011 and started in October 2011) for this research project entitled "Integrated genomic analysis of the response to neoadjuvant chemo-radiotherapy in the treatment of reductive and locally advanced pancreatic adenocarcinoma" for this project at present, still in progress and which should be concluded in October 2013, I personally proceeded to the drafting of the project aswell as to its direct**realization,** this PRIN project has as its coordinating centerthe University ofPisa (Prof. Boggi), the Universities of Turin, Florence, Trieste also participated in this project. Extensive and abstract reviews have emerged from this project. (Publication  **Characterization of pancreatic ductal adenocarcinoma using whole transcriptome sequencing and copy number annalisys by single-nucleotide polymorphism array**. **Molecular Medicine Reports**)

**PROJECT YOUNG RESEARCHERS CALL A. LIBERATI UNIREGIONE 2013**

Respable and coordinator of the mainresearch unit of the Project Young Researchers winner of the Call AndreaLiberati Uniregione, entitled " Whole *trascriptome paired end sequencing in pancreatic cancer and precursor lesions: from early dectetion to therapeutic implication*". At the heart of the project is the massive sequencing analysis of cell transcribing (RNA - Seq) both of tissue samples of pancreatic ductal carcinoma (PDA) and of its precursor lesions (PMIs), with the aim of improving knowledge of the molecular biology of this tumor still characterized by a bad prognosis and a scarcity of therapeutic weapons available to the clinician. The research therefore involves the collection of 50 bioptic or surgical samples of pancreatic ductal adenocarcinoma at different stages of disease and IPMN. After isolation of nucleic acids, massive sequencing of the transcrime will be carried out on the Illumina Hi - ScanSQ platform and the results obtained will be subjected to bioinformatics analysis to operate a systematic filtering of the data, selecting significant mutation events. The data were validated by comparison with DNA analysis obtained from peripheral blood and paraffin tumor tissue samples obtained from a wider set of retrospective samples, in order to identify single nucleotide variants and fusion transcribed of real clinical interest. Theresults obtained were compared with those of the main similar studies available in the literature with a view to carrying out a systematic review of the subject. (Publication  **Copy number gain of chromosome 3q is a recurrent event in patients with intraductal papillary mucinous neoplasm (IPMN) associated with disease progression**,'ONCOTARGET')

**COLLABORATIONS WITH ITALIAN AND FOREIGN UNIVERSITIES**

* Columbia University, USA: Adrenergic-Neurotrophin Feedforward Loop Promotes Pancreatic Cancer (Scientific article ***β2* Adrenergic-Neurotrophin Feedforward Loop Promotes Pancreatic Cancer**, «**CANCER CELL**»,)
* University Medical Center Rotterdam, Paesi Bassi: PANCREATIC CYST SURVEILLANCE IMPOSES LOW PSYCHOLOGICAL BURDEN: THE PACYFIC STUDY - Kasper A. Overbeek
* San Raffaele, Milano: Guideline Application in Real world: multi-Institutional Based survey of Adjuvant and first Line pancreatic Ductal adenocarcinoma treatment in Italy” - Prot. GARIBALDI - Promoted by Associazione Italiana Oncologia Medica (AIOM) - DOTT. MICHELE RENI
* University of Pisa: collaboration within the PRIN 2009 project and presentation of the current PRIN 2017 project, Prof. U. Boggi (model A coordinator of the entire project)
* University of Verona: collaboration within the PRIN 2017 project.

**CURRICULUM OF CLINICAL-CARE ACTIVITIES**

* Since December 1994 she has attended the **Institute of Medical Clinic of the University of Bologna** as a university student collaborating **with Prof. G. Biasco** in following patients suffering from neoplastic pathology.
* This frequency continued as a resident in Oncology (A.A. 1997/98) until September 1998, when she moved to the Institute of **Haematology and Medical Oncology** (tutor Prof. G. Biasco), where she continued to follow the diagnostic and therapeutic process of patients suffering from neoplasm of the gastro-intestinal tract (colon, pancreas, stomach), ovarian, pulmonary, mammary and cutaneous.
* Between November 7, 2000 to February 3th, 2001 he attended **the Mammography Center,** personally performing about 200 ultrasounds of the udder, 20 galactographs, 70 eco-guided breast biopsies.
* Winner of the **Scholarship** at the Health Company of the Policlinico Sant'Orsola-Malpighi of Bologna, she has carried out specialized activities in Oncology at **the Institute of Haematology and Medical Oncology L. and A. Seragnoli** **from 26/11/01** **to 25/11/02,** carrying out patient visits, chemotherapy treatments, Day Hospital activities, follow-up of cancer patients and patients inserted as part of controlled clinical trials.
* From June 2003 to September 2006 he carried out specialized activities with carrying out the clinical oncology activity related to the experimentation of new pharmaceutical products and application of new clinical trials with Professional Free Contracts, renewed every time at the deadline (June 2003-December 2004, January 2004-April 2004, May 2004-December 2004, January 2005-June 2005 and July 2005-December 2005, January 2006-September 2006) always at the Institute of **Haematology and Medical Oncology L. and A. Seragnoli** of the Policlinico Sant'Orsola-Malpighi of Bologna. The main tasks carried out were: Head of the Day Hospital Oncology, Head of Clinics, Corporate Referent for the SSD Medical Oncology Prof. Biasco of Quality.
* Since October 1, 2006 he has continued to carry out clinical-assistance activities at the SSD of Medical Oncology Prof. Biasco to this day as Medical **Assistant Researcher.**
* Assignment of professional management position in Medical Oncology pursuant to art. 27 paragraph 1 - lit. D of the CCNL/2000 from 01/12/2007 to 30/11/2011, from 01/12/2011 to 25/09/2015 assignment of initial specialist professional management position in Medical Oncology pursuant to art. 27 paragraph 1 letter c CCNL/2000, from 26/09/2015 to all conferral of professional management position specialized in Medical Oncology pursuant to art. 27 paragraph 1 lit.C CCNL/2000.
* During these years until 31/10/2017 she was Head **of Clinics** and **Day Hospital,** she contributed to the computerized reorganization of outpatient activity divided by specialist area.
* He participated as a referent of the SSD Prof. Biasco in departmental projects aimed at evaluation, early identification and clinical risk management.
* He also participated as a referent of the SSD Prof. Biasco in the drafting of the medical record of the Unified Day Hospital within the Department of Haematology, Oncology and Laboratory Medicine.
* **Appointed RDQ of the SSD Medical Oncology Prof.** Biasco from l 2010 to 31/05/2015, she dealt with the procedures for the accreditation of the aforementioned SSD in 2010;
* **Responsible for the Specialist Clinic of Pancreatic Neoplasms and during these years about** 3 00 cases of patients per year suffering from this neoplasm have been evaluated;
* **Referent for the SSD Medical Oncology Prof. Biasco within the Multidisciplinary Group of the Sant'Orsola-Malpighi Polyclinic Company (NEOPAN) of the treatment of pancreatic cancer;**
* From June 2018 to today component of the Hepatobiliary pancreatic Day Service.
* **Head of the General Clinic from 2006 to October 2017** where other patients with pathologies of the gastroenteric district, breast, lung and melanoma were followed.
* Drafting of the PDTA document "Le neoplasie del Pancreas", 2017, Bologna, as Head of the Oncology Clinic of the exocrine pancreas of the UO of Medical Oncology.
* This activity can be exemplified by the performance numbers reported, for the year **2018:**
* Access in Day Hospital: ~5.500
* Chemotherapies: ~4,800
* Outpatient visits: ~1.500

**PARTICIPATION IN FURTHER TRAINING COURSES AND CONFERENCES**

He has participated in several conferences and/or refresher courses obtaining over 650 Training Credits.

* Conference on the theme: "Molecular biology for modern medicine: current events and perspectives in the Company". S. Orsola-Malpighi". Bologna, 10 October 1997.
* Joint meeting on "Section of computer tomography, section of gastroenterological radiology", Rimini, 13-15 November 1997.
* Scientific meeting on "Treatment of rectum cancer", Bologna 18 November 1997.
* FONCaM meeting and study day on breast cancer, Bologna, 21 November 1997.
* Third International Melanoma Conference: from biology to clinic. Forlì, 28-29 October 1998.
* 23rd ESMO Congress, Athens – Greece, 6-10 November 1998.
* Parallel course: "Implantable systems and infusion therapies in oncology: methodological aspects and clinical applications". Bologna, 27 November 1998.
* BLS course by category B. Bologna 16-17 February 1999.
* I interdisciplinary meeting of thoracic-pulmonary pathology, Bologna, 23 April 1999.
* Refresher course: "Deltec CAD programmable portable microinfusers". Bologna, 3-4 May 1999.
* Parallel course: "Adenocarcinoma del pancreas", Padua, 8 May 1999.
* VII Technical meeting of the I.T.M.O. group: "Studies in progress and to be activated". Milan, 14 June 1999.
* Ii International Conference: "The global approach of cancer patients". Bellaria - Rimini, 29 September-2 October 1999.
* "Cancer vaccine therapy: a hope or a reality?" Bologna, 21 February 2000.
* VIII technical meeting of the I.T.M.O. group: "Neuroendocrine neoplasms: new classifications, new therapies". Milan, 14 April 2000.
* The interdisciplinary meeting of thoracopulmonary pathology, Bologna, 12 May 2000.
* Conference: "The integrated treatment of non-microcytoma lung cancer". Bologna, 30 May 2000.
* II European Conference: perspectives in colorectal cancer. Barcelona – Spain, June, 16-17 2000.
* Extraordinary congress of gastroenterology: "New trance in digestive diseases", Bologna, 1-5 July 2000.
* Participation in the World Meeting of University Professors, held as part of the Jubilee of Universities in Rome on 9 and 10 September 2000.
* International Symposium liver metastases. Bologna, September, 21-23 2000.
* Seminar n° 9 of the I.T.M.O. group: "Breast neoplasms and ormonotherapy". Milan, 27 November 2000
* Fourth AIOM National Conference: "Colorectal Cancer". Bologna, 4-6 March 2001.
* Helsinn Investigator Meeting: Palonosetron Development Program Palo-99-03/05/06. Monaco di Baviera, 31/03/01.
* 3rd National Conference: "The global approach to cancer patients". Rimini, 6-7-8 June 2001.
* "Malignant Mesothelioma: New acquisitions and therapeutic strategies". Bologna, 13 June 2001.
* 2nd Seminar of Digestive Oncology. Frascati, RM, 2-4 July 2001.
* 3rd National Congress of Medical Oncology, Naples, 4-7 November 2001.
* "New ways to better cancer treatment": Ravenna, 23/11/01.
* "Oncologist-Patient Communication": Grottaferrata (RM), 4-5 December 2001.
* Fourth meeting Specialists in Oncology, Montecatini Terme, 21-22-23 March 2002.
* “Infusion chemotherapy and drug-delivery devices”, Roma, 17-18 April 2002. 12 Credits ECM
* The American Society of Clinical Oncology 2002 Annual Meeting, Orlando, Florida, USA, 18-21 Maggio 2002.
* "Interventional strategies in coronary syndromes", Rimini, 8 June 2002. 4 ECM Training Credits.
* Internship in Oncology "Breast cancers", Bologna, 17-21 June 2002. 31 ECM Training Credits.
* "Skin cancers: melanomas and non-melanomas", Vasto (CH), 28 June 2002.
* Internship in Oncology "Innovative Treatments in Oncology", Bologna, 23-27 September 2002. 27 ECM Training Credits.
* 4th National Congress of Medical Oncology, Turin, 28 September - 1 October 2002. 20 ECM Training Credits.
* I Institutional course for locoregional therapies, Milan, 23 October 2002. 8 ECM Training Credits.
* "European Quality Week – Managing Change", Bologna, 19 November 2002.
* Course on Cancer of the Gastrointestinal tract, Roma, 16-18 December 2002.
* First European Palonosetron Event, Lugano, 7-9 February 2003.
* Residential course: Problems in the management of the patient with neoplasm of the gastrointestinal tract. 2nd Annual Course National Academy of Medicine, Lido di Camaiore (LU), 21-22 March 2003. 10 ECM Training Credits.
* Internship in Oncology: "Anaemia, thrombosis and cancer", Bologna, 24-28 March 2003. 25 ECM Training Credits.
* Internship in: "Predictive Medicine in Oncology", Bologna, 16-20 June 2003. 26 ECM Training Credits.
* “Third update on Helicobacter pylori research and other emerging issues on digestive cancer prevention”, Bologna, 25-28 June 2003.
* Fifth AIOM National Congress, Rome, 21-24 October 2003. 17 ECM Training Credits.
* "New structure of Health Bologna and the role of the University": Bologna, 15 December 2003.
* Conference: Master's Reading, "Neurological Paraneoplastic Syndromes", Bologna, 10 February 2004.
* Seminars of Gastroenterology: "The focal lesions of the pancreas: diagnostic and therapeutic aspects", Bologna, 27 February 2004.
* Internship in Oncology: "Il cancro del colon retto", Bologna, 8-10 March 2004. 17 ECM Training Credits.
* National Congress: "The culture of anaemia to look to the future", Genoa, 2 April 2004. 12 ECM Training Credits.
* “Advances in the treatment of breast cancer”, Global Experts Summit, Budapest, 16-17 April 2004.
* "The States General of Cancer Patients – the condition of the cancer patient: reality and prospects", Forlì, 22 April 2004. 2 ECM Training Credits.
* Scientific meeting "Oral chemotherapy in oncology", Bologna, 4 May 2004. 2 ECM Training Credits.
* Training and updating meetings in Oncology: "Oral therapies: pharmacoeconomy and management", Bologna, 4 May 2004.
* "New knowledge on cancer and clinical implications in opioid therapy", Dogliani (CN), 18-19 June 2004. 10 ECM Training Credits.
* Internship in Oncology: "Infections in oncology and haematology", Bologna, 21-23 June 2004. 19 ECM Training Credits.
* 10th International Congress of the Metastasis Research Society “Progress against tumour progression”, Genova, 17-20 September 2004.
* VI National Congress of Medical Oncology, Bologna, 21-24 September 2004. . 6 ECM Training Credits.
* 29th ESMO Congress, Vienna, 29 October – 2 November 2004;
* Corso “Multidisciplinary treatment of soft tissue sarcoma”, Vienna, 30 October, 2004. 3 Credits ECM.
* "Molecular targeting" course, Vienna, 31 October 2004. 4 ECM Training Credits.
* Internship in Oncology: "Il cancro dello stomaco", Bologna, 22-24 November 2004. 14 ECM Training Credits.
* Oncology Seminars 2005: "Melanoma", Bologna, 27 April 2005. 2 ECM Training Credits.
* Course entitled: "Gastroenteropathy endocrine tumors", Bologna, 25-27 May 2005.
* Stage in Oncology: “Targeted therapies in oncology”, Bologna, 20-22 June 2005. 16 Credits ECM.
* Avita Investigator Meeting, Budapest, 7-8 September 2005.
* Internship in Oncology: "Brain tumors, melanoma, head-neck tumors". Bologna, 21-23 November 2005. 17 ECM Training Credits.
* NETs Symposia: "Endocrine tumors of the digestive system". Frascati, 11-12 December 2005: "Endocrine tumors of the stomach".
* "Melanoma: updates for better clinical practice". Bologna, 24 January 2006. 4 ECM training credits.
* "Colon and ovary cancer: innovative therapeutic orientations in localized disease and peritoneal carcinosis". Bentivoglio Castle, February 10, 2006.
* "The way of healing her2 breast cancer positive". Modena, 24 February 2006.
* NETs Symposia: "Endocrine tumors of the digestive system". Frascati, 12-13 March 2006: "Endocrine tumors of the pancreas".
* "The treatment of colorectal cancer in 2006". Bologna, 24 March 2006.
* Interactive "Lung cancer conference". Lisbon, 6-7 May 2006.
* Residential course: "Therapies aimed at molecular targets: promises, problems, progress". Modena, 18-19 May 2006. 12 Training Credits.
* Scientific meeting: "Pancreatic cancer: a clinical update". Bologna, 16 June 2006.
* Internship in Oncology: "Support Therapies". Bologna, 26-28 June. 14 ECM Training Credits.
* 8th World Congress on Gastrointestinal Cancer. Barcellona, 28 June – 1 July 2006.
* Certificate of participation in the conference "New trends in molecular imaging and nuclear medicine", Bologna, 14-15 September 2006.
* XXX National Congress of the Italian Association for the Study of the Pancreas, Milan, 21-23 September 2006. 9 Training Credits
* Conference "Pancreatic cancers and acute pancreatitis", Matera 6-7 October 2006
* VIII National Congress of Medical Oncology, Milan, 18-21 November 2006.
* Participation in the meeting of the Working Group on "Advanced Therapy of the Colorectal cancer" held in Bologna on November 9, 2006.
* Internship in Oncology "Immunology in Oncology", Bologna, 4-6 December 2006. 13 Training Credits.
* Investigator Meeting 30-31 October 2007, Roma, “ARC Study” (A4061028).
* Workshop on GIST – "Clinical appropriateness and integration of treatment processes", 16 November 2007, Bologna. 6 Training Credits.
* "Antiangiogenesis and risk of thrombosis", 21 November 2007, Bologna.
* Participation as An Investigator at the ARC Study Investigator Meeting, 30-31 October 2007, Rome.
* Participation in the course of "BLSD performer", basic cardiopulmonary resuscitation and early defibrillation, with the achievement of a certificate, 12 March 2008, Bologna.
* Participation as speaker at the "Highlights in management of gastrointestinal cancer", 11-12 April 2008, Rome.
* Participation in the presentation meeting of the multicenter nursing research study "Use of acupression in the management of nausea and vomiting induced by chemotherapy: randomized blind study", Florence 15 September 2008.
* Participation in the Advanced Course "Gastroenteropancreatic Endocrine Tumors", Bologna 24-26 September 2008. 14 Training Credits.
* Participation in the meeting "The surgery of rare tumors and carcinosis", Bologna 2 October 2008. 4 Training Credits.
* XXXII National Congress Italian Association for the Study of the Pancreas, Montecatini Terme, 2-4 October 2008. 8 Training Credits.
* X National Congress of Medical Oncology, Verona, 11-14 October 2008. 22 Training Credits.
* "Therapeutic appropriateness in the management of the patient with renal cancer", 14 November 2008, Bologna. 2 Training Credits.
* "Star network III – Scientific meeting: integrated and translated treatments of tumors of the gastroenteric district", 26 November 2008, Bologna. 3 Training Credits.
* “Eage postgraduate course on gastrointestinal and liver oncology”, 12-14 February 2009, Roma.
* Participation in the "NET Stage Advanced – Aggiornamenti, evidence and exchange of experiences of patients with neuroendocrine tumors", 24-25 September 2009, Bologna. 11 Training Credits.
* 11th National Congress of Medical Oncology 10-13 October, 2009: Milan, Italy. 13 Credits.
* XXXIII National Congress of the Italian Association for the Study of the Pancreas (A.I.S.P), Rozzano, 15-17 October 2009. 12 Training Credits.
* Participation in quality of investigator to Investigator meeting CO-101-001 “A phase II randomized open label multicenter study comparing CO-101-001 with Gemcitabine as first line therapy in patients with metastatic pancreatic adenocarcinoma”, 1 May 2010, Praga.
* XXXIV National Congress of the Italian Association for the Study of the Pancreas (AISP), Peschiera del Garda, 7-9 October 2010, 9 Training Credits.
* XII AIOM National Congress, Rome, 6-8 November 2010. 20 Training Credits.
* Palliative Care Models, Bentivoglio (BO), March 25, 2011.
* Advances in Oncology: updates on research supported with "Vanini Cavagnino" funds, 16 April 2011.
* XXXV Congress of the Italian Association for the Study of the Pancreas (AISP), 13-15 October 2011, Verona.
* The seminars of Bentivoglio, Communication in Medicine, 11 November 2011, Bentivoglio (BO). 7 Training Credits.
* Training in Palliative Care, Seminar held in Bentivoglio (BO) on January 27, 2012.
* Hepato-bilio-pancreatic surgery, 14-15 March 2012, Bologna, 18 Training Credits.
* 44th Annual Meeting of European Pancreatic Club, 20-23 June, Praga,2012 Repubblica Ceca.
* XXXVI Annual Meeting Italian Association for the study of the pancreas (AISP), 4-6 October 2012, Bologna.
* XXXVII Annual Meeting Italian Association for the study of the pancreas (AISP), 19-21 September 2013, Bologna.
* Participation as Discussant in the multidisciplinary Interactive Comparison "Pancreatic Cystic Incidentalomi", Rimini, 26 October 2013.
* Participation as expert delegate to the "I Pancreatic Cancer Forum 2013", 29-30 November 2013, Madrid.
* XXXVIII Annual Meeting Italian Association for the study of the pancreas (AISP), 18-20 September 2014, Bologna.
* II Pancreatic Cancer Forum 2014, Munich, 28-29 November 2014.
* Coordinator of the Bologna office of the Web Meeting "news from ASCO GI 2015", held in Bologna on January 23, 2015;
* Stage in Web “Highlights ASCO Gastrointestinal Cancer Symposium, 26 January 2015, Malpighi. Hospital, Bologna.
* 2nd Onco Workshop "Nanotechnology and Innovation: New Frontiers in Cancer Treatment", Bari, 27-28 March 2015.
* 47th Annual Meeting of the European Pancreatic Club, Poster presentation, Toledo, 24-26 June 2015.
* 40 ESMO Congress, Vienna, 25-29 September 2015. XXXIX AISP National Congress: Milan, 22-24 October 2015.
* Speaker at the II Women Workshop "The new frontiers of nanotechnology in solid tumors", Peschiera del Garda, 30 October 2015.
* III Pancreatic Cancer Forum, as Expert Delegate, held in Milan on 6-7 November 2015.
* National Workshop "Advances in Oncology: Focus on pancreatic cancer", Verona, 6-7 May 2016.
* ACCMED Conference "Wide angle in Oncology. Focus on support therapies", Bologna, 9-10 May 2016.
* Speaker at meet the expert "pancreatic cancer" with report entitled "Metastatic disease in the fragile patient", Ferrara, 22 June 2016.
* Speaker at the MGB I Meeting of Gastroenterology in Bologna: New frontiers of echo endoscopy in biliopancreatic pathology: a multidisciplinary approach, 12 September 2016.
* Participation to Central European Cooperative Oncology Group (CECOG), Pancreatic Cancer Academy, Vienna, 10-12 November 2016.
* Participation in the Congress "Italian University Medical Oncology between training, research and assistance", COMU National Meeting, 3-4 February 2017.
* Lecturer at the conference "Pancreatic cancer: new challenges, new hopes?", 31 March 2017, Bologna.
* Speaker at the Workshop "Pancreatic cancer and precancerousis, Special Clinical Cases", 1 April 2017, Bologna.
* AIOM 2017, 16-17 June 2017, Bologna.
* ESMO 2017 Congress, 8-12 September 2017, Madrid, Spain.
* Conference "Reference for rare tumors", 27 September 2017, Bologna.
* Academy of Palliative Medicine Sciences, "The international perspective of Palliative Care: from needs to solutions", 28 September 2017, Bologna.
* XLI AISP Congress, 5-7 October 2017, Rozzano (MI).
* Speaker at the Conference World Pancreatic Cancer Day, 16 November 2017, Bologna.
* Conference "Open issues in pancreatic cancer 2017", 28 November 2017, Milan.
* Congress "Asbestos: other neoplasms besides mesothelioma", 22 January 2018.
* Participation in the Congress "Italian University Medical Oncology between training, research and assistance", COMU National Meeting, 2-3 February 2018.
* Seminar Global control of cancer, the role of IARC with a special focus on the IARC monographs, 15 February 2018, Bologna.
* Conference "Oncology is a team game", 9-10 March 2018, Bologna.
* Speaker at the conference "Pancreatic tumors from epidemiology to new therapists", Chieti, 27 April 2018.
* Relator to Interactive Web Conference Pancreatic Cancer, Milano, 8 June 2018, at Aemilia Hotel of Bologna.
* Participation to training event “Trust: therapeutic route map for a successful treatment of melanoma”, Bologna 17 September 2018, 5/2 credits.
* Participation in the ESMO 2018 Congress, Munich, 19/10-23/10 2018.
* Invitation to participate as Delegation Expert at ECOG Pancreas cancer academy, Amsterdam, 30/11-1/12 2018.
* Participation as expert oncologist at the Advisory Board "Tumors of the pancreas: optimization of the therapeutic path in a multidisciplinary perspective", December 11, 2018, Milan.
* Participation in the 1st GICO Meeting: Intrahepatic cholagiocarcinoma,29 January 2019, Bologna
* Participation in "Oncology is a team game", Bologna, 15-16 March 2019
* Participation in the event "Melanoma in Bologna", 29 March 2019
* Participation in the EPC 2019 from 26 to 29 June in Bergen (Norway) with poster presentation "Searching for novel multimodal treatment in oligometastatic pancreatic adenocarcinoma: a case report".
* Participation in the nanomedicine conference Nutrition Surgery "The synergistic approach to the cancer patient", Rome 2 July 2019.
* Participation in the CONFERENCE NATIONAL MEETING COMU: from training to oncology of the future, 28-29 November 2019.
* Poster presentation at EPC 2020 webinar meeting, Paris 1-2 July 2020

**Publications**

2021 – Article in scientific journal

Riccardo Casadei, Claudio Ricci, Carlo Ingaldi, Alessandro Cornacchia, Marina Migliori, **Mariacristina Di Marco**, Nico Pagano, Carla Serra, Laura Alberici, Francesco Minni **External validation of nomogram for predicting malignant intraductal papillary mucinous neoplasm (IPMN): from the theory to the clinical practice using the decision curve analysis model** Updates in Surgery https://doi.org/10.1007/s13304-021-00999-4

2021 – Article in scientific journal

U. Peretti, A. Cavaliere, M. Niger, G. Tortora, **M. C. Di Marco**, M. G. Rodriquenz, F. Centonze, I. G. Rapposelli, G. Giordano, F. De Vita, L. Stuppia, A. Avallone, M. Ratti, C. Paratore, L. G. Forti, G. Orsi, M. M. Valente, M. Gaule, M. Macchini, P. Carrera, S. Calzavara, M. Simbolo, D. Melisi, F. De Braud, L. Salvatore, S. De Lorenzo, C. Chiarazzo, M. Falconi, S. Cascinu, M. Milella, M. Reni **Germinal BRCA1-2 pathogenic variants (gBRCA1-2pv) and pancreatic cancer: epidemiology of an Italian patient cohort** ESMO OPEN, Vol. 6 – Issue 1 – 2021 https://doi.org/10.1016/j.esmoop.2020.100032

2020 – Article in scientific journal

G Brandi, M Deserti, A Palloni, D Turchetti, R Zuntini, F Pedica, G Frega, S De Lorenzo, F Abbati, A Rizzo, **M Di Marco**, F Massari, S Tavolari **INTRAHEPATIC CHOLANGIOCARCINOMA DEVELOPMENT IN A PATIENT WITH A NOVEL BAP1 GERMLINE MUTATION AND LOW EXPOSURE TO ASBESTOS** Cancer Genetics S2210-7762(20)30276-3 DOI: https://doi.org/10.1016/j.cancergen.2020.10.001 Vol. 248, pp 57-62, ottobre 2020

2020 – Article in scientific journal

**Mariacristina Di Marco**, Riccardo Carloni, Stefania De Lorenzo, Cristina Mosconi, Andrea Palloni, Elisa Grassi, Daria Maria Filippini, Angela Dalia Ricci, Alessandro Rizzo, Alessandro Di Federico, Donatella Santini, Daniela Turchetti, Claudio Ricci, Carlo Ingaldi, Laura Alberici, Francesco Minni, Rita Golfieri, Giovanni Brandi, Riccardo Casadei **Pancreatic mucinous cystadenocarcinoma in a patient harbouring BRCA1 germline mutation effectively treated with olaparib: A case report** World Journal of Gastrointestinal Oncology, 2020 December 15; 12(12): 0-0 DOI: 10.4251/wjgo.v12.i12.0000 ISSN 1948-5204

2020 – Article in scientific journal

Riccardo Casadei, Claudio Ricci, Carlo Ingaldi, Laura Alberici, **Mariacristina Di Marco**, Alessandra Guido, Francesco Minni, Carla Serra **Intraoperative electrochemotherapy in locally advanced pancreatic cancer: indications, techniques and results - a single‑centre experience** Updates in Surgery (2020) 72:1089–1096 https://doi.org/10.1007/s13304-020-00782-x

Abstract ESMO (2020)

A. Rizzo, A. Ricci, S. Tavolari, C. Felicani, A. Palloni, G. Frega, S. De Lorenzo, M. Deserti, F. Vasuri, M. Nigro, F. Abbati, A. Di Federico, M. Mosca, V. Mollica, I. Maggio, M. Salati, **M. Di Marco**, F. Tovoli, M. Cescon, A. Pinna, C. Serra, G. Brandi **Microwave ablation versus radiofrequency ablation in BCLC-A hepatocellular carcinoma: A systematic review and meta-analysis of randomized controlled trials** Annals of Oncology, P23, Volume 31 – Issue S3, S96.

2020 – Abstract ASCO 2020

**Mariacristina Di Marco**, Claudio Ricci, Riccardo Carloni, Elisa Grassi, Stefania De Lorenzo, Andrea Palloni, Francesca Abbati, Elisa Andrini, Alessandro Di Federico, Angela Dalia Ricci, Carlo Ingaldi, Carla Serra, Laura Alberici, Emilio De Raffele, Alessandra Guido, Francesco Minni, Alessandro Rizzo, Giovanni Brandi, Maria A. Pantaleo, Riccardo Casadei **Intraoperative electrochemotherapy in locally advanced pancreatic cancer: Results and impact on quality of life. a single centre experience**. ASCO 2020.

2020 – Abstract AISP

Umberto Peretti, Michele Milella, Giampaolo Tortora, **Maria Cristina Di Marco**, Federico Centonze, Maria Grazia Rodriquenz, Meldola, Guido Giordano, Ferdinando De Vita, Margherita Ratti, Chiara Paratore, Giulia Orsi, Alessandro Cavaliere, Lisa Salvatore, Stefania De Lorenzo, Cinzia Chiarazzo, Marina Macchini, Maria Maddalena Valente, Paola Carrera, Michele Reni **gBRCA1-2 mutations and pancreatic cancer: epidemiology of an Italian patients cohort** AISP 2020.

2020 – Abstract AIOM

Bergamo Francesca, Giommoni Elisa, **Di Marco Maria Cristina**, Cordio Stefano, Artioli Fabrizio, Cardellino Giovanni Gerardo, Spada Massimiliano, Milella Michele, Luppi Gabriele, Silvestris Nicola, Maiello Evaristo, Bozzarelli Silvia, Giordano Monica, Cavanna Luigi, Ghidini Michele, Peretti Umberto, Valente Maria Maddalena, Torri Valter, Porcu Luca, Giugliano Valentina **Guideline Application in Real world: multi-Institutional Based survey of Adjuvant and first Line pancreatic Ductal adenocarcinoma treatment in Italy: the GARIBALDI trial**. Preliminary results XXII AIOM 2020

2020 – Poster EPC

**Mariacristina Di Marco**, Riccardo Carloni, Stefania De Lorenzo, Elisa Grassii, Andrea Palloni, Daria Maria Filippini, Angela Dalia Ricci, Alessandro Rizzo, Alessandro Di Federico, Donatella Santini, Daniela Turchetti, Claudio Ricci, Carlo Ingaldi, Laura Alberici, Francesco Minni, Giovanni Brandi, Riccardo Casadei **Aggressive approach to metastatic pancreatic cystadenocarcinoma in a patient harboring BRCA-1 germline mutation: a case report**. EPC 2020.

Abstract ESMO (2020)

A. Rizzo, A. Ricci, F. Dall’Olio, G. Frega, C. Felicani, G. Ercolani, S. Tavolari, M. Deserti, A. Palloni, S. De Lorenzo, F. Abbati, V. Mollica, I. Maggio, N. Tober, M. Pantaleo, **M. Di Marco**, F. Tovoli, M. Cescon, A. Pinna, A. Ardizzoni, C. Serra, G. Brandi **Role of percutaneous radiofrequency ablation in unresectable, non- metastatic intrahepatic cholangiocarcinoma: A single-institution experience** Annals of Oncology, P-19, Volume 31 - Issue S3, S95.

2020 - Poster

**Di Marco M**, Ricci C, Brandi G, De Lorenzo S, Tovoli F, Carloni R, Palloni A, Abbati F, Grassi E, Guido A, Morganti AG, Nigro MC, Rizzo A, Ricci DA, Alberici L, D’Onofrio M, Minni F, Santini D, Casadei R **Neoadjuvant chemoradiotherapy and surgery versus surgery alone in resectable pancreatic cancer: Long term follow-up results from a single-center prospective, randomized, controlled trial** XXII AIOM 2020, C14

2020 – Article in scientific journal

Alessandra Arcelli, Milly Buwenge, Gabriella Macchia, Federica Bertini, Alessandra Guido, Francesco Deodato, Savino Cilla, Valerio Scotti, Maria Elena Rosetto, Igor Djan, Salvatore Parisi, Gian Carlo Mattiucci, Francesco Cellini, Michele Fiore, Pierluigi Bonomo, Liliana Belgioia, Rita Marina Niespolo, Pietro Gabriele, **Mariacristina Di Marco**, Nicola Simoni, Renzo Mazzarotto, Alessio Giuseppe Morganti **Stereotactic body radiotherapy vs conventionally fractionated chemoradiation in locally advanced pancreatic cancer: A multicenter case‐control study (PAULA‐1)**, Cancer Medicine, 2020, September 10, 9:7879–7887. DOI: 10.1002/cam4.3330

2020 – Article in scientific journal

**Di Marco M**, Carloni R, De Lorenzo S, Grassi E, Palloni A, Formica F, Brocchi S, Filippini DM, Golfieri R, Brandi G. **Long-term survival of two patients with recurrent pancreatic acinar cell carcinoma treated with radiofrequency ablation: A case report**. World Journal of Clinical Cases, 2020, April 6; 8(7): 1241-1250.

2020 – Article in scientific journal

D. M. Filippini, E. Grassi\*, A. Palloni, R. Carloni, R. Casadei, C. Ricci, C. Serra, G. Ercolani, G. Brandi, **M. Di Marco**. **Searching for novel multimodal treatments in oligometastatic pancreatic cancer**. BMC Cancer (2020) 20:271, 1-5.

2020 – Article in scientific journal

Angela Dalia Ricci, Alessandro Rizzo, Marco Novelli, Simona Tavolari, Andrea Palloni, Nastassja Tober, Francesca Abbati, Veronica Mollica, Stefania De Lorenzo, Daniela Turchetti, **Mariacristina Di Marco** and Giovanni Brandi. **Specific Toxicity of Maintenance Olaparib Versus Placebo in Advanced Malignancies: A Systematic Review and Meta-analysis**. ANTICANCER RESEARCH 40: 597-608 (2020)

2020 – Article in scientific journal

Arcelli, Alessandra; Guido, Alessandra; Buwenge, Milly; Simoni, Nicola; Mazzarotto, Renzo; Macchia, Gabriella; Deodato, Francesco; Cilla, Savino; Bonomo, Pierluigi; Scotti, Valerio; Belgioia, Liliana; Tolento, Giorgio; Cellini, Francesco; Grassi, Elisa; **Di Marco, Mariacristina**; Casadei, Riccardo; Morganti, Alessio G; Cammelli, Silvia, **Higher Biologically Effective Dose Predicts Survival in SBRT of Pancreatic Cancer: A Multicentric Analysis (PAULA-1),** «ANTICANCER RESEARCH», 2020, 40, pp. 465-472 - 472

2019 – Article in scientific journal

Morganti A.G.; Cellini F.; Buwenge M.; Arcelli A.; Alfieri S.; Calvo F.A.; Casadei R.; Cilla S.; Deodato F.; Di Gioia G.; **Di Marco M.**; Fuccio L.; Bertini F.; Guido A.; Herman J.M.; Macchia G.; Maidment B.W.; Miller R.C.; Minni F.; Passoni P.; Valentini C.; Re A.; Regine W.F.; Reni M.; Falconi M.; Valentini V.; Mattiucci G.C., **Adjuvant chemoradiation in pancreatic cancer: Impact of radiotherapy dose on survival**, «BMC CANCER», 2019, 19, pp. 1 - 10

2019 – Article in scientific journal

Hammel P.; Kindler H.L.; Reni M.; Van Cutsem E.; MacArulla T.; Hall M.J.; Park J.O.; Hochhauser D.; Arnold D.; Oh D.-Y.; Reinacher-Schick A.; Tortora G.; Algul H.; O'Reilly E.M.; McGuinness D.; Cui K.Y.; Joo S.; Yoo H.K.; Patel N.; Golan T.; Chantrill L.; Goldstein D.; Joubert W.; Pavlakis N.; Tognela A.; Van Cutsem E.; Van Fraeyenhove F.; Van Laethem J.-L.; Peeters M.; Dhani N.; Kavan P.; Lemay F.; Adenis A.; Artru P.; Baba-Hamed N.; Belletier C.; Ben Abdelghani M.; Blanc J.-F.; Borg C.; Coriat R.; Deplanque G.; Faroux R.; Follana P.; Guimbaud R.; El Hajbi F.; Hammel P.; Hautefeuille V.; Malka D.; Metges J.-P.; Tougeron D.; Walter T.; Algul H.; Ettrich T.; Hacker U.T.; Hennes E.; Jacobasch L.; Kanzler S.; Pession U.; Reinacher-Schick A.; Scholz C.; Sinn M.; Stein A.; Strassburg C.; Vogel A.; Ben-Shahar M.; Brenner R.; Epelbaum R.; Geva R.; Gluzman A.; Golan T.; Idelevich E.; Kolin M.; Semenisty V.; Shai A.; Stemmer S.; Yarom N.; Celio L.; Conte P.; Garufi C.; Gianni L.; Leonardi F.; Maiello E.; **Di Marco M**.; Milella M.; Pinto C.; Santini D.; Scartozzi M.; Tortora G.; Vaccaro V.; Vasile E.; Kim J.-W.; Kim J.-W.; Oh D.-Y.; Oh Park J.; Wilmink H.; Gallego R.A.; Ogalla G.D.; Velasco A.G.; Cabanas E.G.; Gomez Martin C.; Ponce C.G.; Saez B.L.; Lopez R.; MacArulla T.; Martin A.M.; Pazo R.; Pijaume C.P.; Rodriguez J.; Yaya-Tur R.; Arora A.; Anthoney D.A.; Jeffrey Evans T.R.; Harrison M.; Hochhauser D.; Palmer D.; Sarker D.; Starling N.; Valle J.; Wall L.; Agajanian R.; Bearden J.; Bekaii-Saab T.; Carter C.; Cohen D.; Distefano A.; Dragovich T.; Ejadi S.; Ford J.; Grabelsky S.; Hall M.; Hochster H.; Hosein P.; Javle M.; Kindler H.; Lacy J.; Laheru D.; Leong S.; Lowery M.; Marsh R.; Noonan A.; Oberstein P.; Ocean A.; O'Reilly E.; Ryan D.; Seery T.; Subramaniam S.; Van Echo D.; Wang-Gillam A.; Weekes C.; Welch S., **Health-related quality of life in patients with a germline BRCA mutation and metastatic pancreatic cancer receiving maintenance olaparib**, «ANNALS OF ONCOLOGY», 2019, 30, pp. 1959 – 1968

2019 – Article in scientific journal

Overbeek K.A.; Camps A.; of Reed P.A.; **Di Marco M.** ; Zerboni G.; by Hooft J.E.; Carrara S.; Ricci C.; Gonda T.A.; Clean E.; Polkowski M.; Beyer G.; Honkoop P.; van der Waaij L.A.; Casadei R.; Capurso G.; Erler N.S.; Bruno M.J.; Bleiker E.M.A.; Cahen D.L.; Bruno M.J.; Cahen D.L.; of Reed P.A.; Overbeek K.A.; Levink I.J.M.; Koopmann B.; Besselink M.G.H.; del Chiaro M.; Lerch M.M.; Wallace M.B.; of Ballegooijen M.; Biermann K.; Bleiker E.M.A.; Bulbs T.H.L.; Fockens P.; The Chef I.M.C.M.; Looijenga L.H.J.; Peppelenbosch M.P.; Verhagen-Oldenampsen J.H.E.; Arcidiacono P.G.; Capurso G.; Bergmann J.; of Berkel A.; Beyer G.; Bijlsma R.; Braat H.; Carrara S.; Czako L.; of Erp-van der Steen H.; Ganesh S.; of Geenen E.; Gonda T.; High C.; Honkoop P.; by Hooft J.E.; Jansen J.; Larghi A.; van Leeuwenburgh I.; Laukkarinen J.; Lelyveld N.; Lerch M.; di Marco M.C.; Ricci C.; Casadei R.; Rau E.P.; Perk L.; Polkowski M.; Pukitits A.; Quispel R.; Radenkovic D.; Seicean A.; Schwartz T.; Clean E.J.; of Soest E.; Tan A.; Venneman N.G.; Fox P.; Voorburg A.; van der Waaij L.A.; Wijkerslooth L.R.H.; Zerboni G.; della Fave G.; Withouthouse B., **Pancreatic cyst surveillance imposes low psychological burden**,«PANCREATOLOGY», 2019, 19, pp. 1061 - 1066

2019 – Article in scientific journal

Claudio Ricci, Carlo Ingaldi, Marina Migliori, Nico Pagano, Donatella Santini, Laura Alberici, Carla Serra, Lucia Calculli, Mariacristina Di Marco, Francesco Minni, Riccardo Casadei. **What is the Outcome of Patients Affected by Intraductal Papillary Mucinous Neoplasms Without High-risk Stigmata?**  **A Single Centre Retrospective Study.**  Accepted in Pancreas 2019 in press.

2019 - Poster

DM Filippini, E Grassi, A Palloni, S. Vecchiarelli, G. Ercolani, C. Ricci, R. Casadei, M Di Marco. **Searching for novel multimodal treatments in oligometastatic pancreatic adenocarcinoma: a case report.** Pancreatology, Vol 19 n S1 2019, Poster P3-17 S62.

2019 – Article in scientific journal

Morganti AG, Cellini F, Buwenge M, Arcelli A, Alfieri S, Calvo FA, Casadei R, Cilla S, Deodato F, Di Gioia G, Di Marco M, Fuccio L, Bertini F, Guido A, Herman JM, Macchia G, Maidment BW 3rd, Miller RC, Minni F, Passoni P, Valentini C, Re A, Regine WF, Reni M, Falconi M, Valentini V, Mattiucci GC.  **Adjuvant chemoradiation in pancreatic cancer: impact of radiotherapy dose on survival**. BMC Cancer. 2019 Jun 11;19(1):569

2018 - Article in scientific journal

Casadei, Riccardo; Ricci, Claudio; Taffurelli, Giovanni; Pacilio, Carlo Alberto; Santini, Donatella; **Di Marco, Mariacristina**; Minni, Francesco, **Multicolour versus monocolour inking specimens after pancreaticoduodenectomy for periampullary cancer: A single centre prospective randomised clinical trial**, «INTERNATIONAL JOURNAL OF SURGERY», 2018, 0, pp. 2 - 11

2018 - Article in scientific journal

Grassi, Elisa; Durante, Sandra; Astolfi, Annalisa; Tarantino, Giuseppe; Indio, Valentina; Freier, Eva; Vecchiarelli, Silvia; Ricci, Claudio; Casadei, Riccardo; Formica, Francesca; Filippini, DARIA MARIA; Comito, Francesca; Serra, Carla; Santini, Donatella; D'Errico, Antonietta; Minni, Francesco; Biasco, Guido; **Di Marco, Mariacristina**, **Mutational burden of resectable pancreatic cancer, as determined by whole transcriptome and whole exome sequencing, predicts a poor prognosis**, «INTERNATIONAL JOURNAL OF ONCOLOGY», 2018, 00, pp. 1 - 9

2018 - Article in scientific journal

Comito, Francesca; Grassi, Elisa; Poerio, Antonio; Freier, Eva; Calculli, Lucia; Zompatori, Maurizio; Ricci, Claudio; Casadei, Riccardo; **Di Marco, Mariacristina**, **Organizing pneumonia after pancreatic cancer treatment with nab-paclitaxel and gemcitabine: a case report**, «BJR CASE REPORTS», 2018, 4, pp. 1 - 5

2017 – Article in scientific journal

Renz, Bernhard W.; Takahashi, Ryota; Tanaka, Takayuki; Macchini, Marina; Hayakawa, Yoku; Dantes, Zahra; Maurer, H. Carlo; Chen, Xiaowei; Jiang, Zhengyu; Westphalen, C. Benedikt; Ilmer, Matthias; Valenti, Giovanni; Mohanta, Sarajo K.; Habenicht, Andreas J. R.; Middelhoff, Moritz; Chu, Timothy; Nagar, Karan; Tailor, Yagnesh; Casadei, Riccardo; **Di Marco, Mariacristina**; Kleespies, Axel; Friedman, Richard A.; Remotti, Helen; Reichert, Maximilian; Worthley, Daniel L.; Neumann, Jens; Werner, Jens; Iuga, Alina C.; Olive, Kenneth P.; Wang, Timothy C., ***β2* Adrenergic-Neurotrophin Feedforward Loop Promotes Pancreatic Cancer**, «**CANCER CELL**», 2017, 33, pp. 75-90.e7 - 90.e7

2017 - Abstract

Renz, Bernhard W.; Mayer, Barbara; Macchini, Marina; Wang, Timothy C.; Casadei, Riccardo; **Di Marco, Mariacristina**; Kleespies, Axel; Werner, Jens, **Clinical impact of nonselective beta-blockers on survival in patients with pancreatic cancer- revival of well known drugs?** , «PANCREATOLOGY», 2017, 17, pp. 32 - 33

2017 - Abstract

Grassi, Elisa; Durante, Sandra; Astolfi, Annalisa; Tarantino, Giuseppe; Indio, Valentina; Freier, Eva; Formica, Francesca; Filippini, DARIA MARIA; Ricci, Claudio; Casadei, Riccardo; Serra, Carla; Santini, Donatella; D'Errico, Antonietta; Pinna, ANTONIO DANIELE; Minni, Francesco; Biasco, Guido; **Di Marco, Mariacristina**, **Higher number of known pancreatic cancer mutations highlighted by whole-transcripto- me and whole-exome sequencing predicts cli- nical outcome in early stage patients**, «MINERVA GASTROENTEROLOGICA E DIETOLOGICA», 2017, 63, pp. 21 - 21

2017 - Article in scientific journal

Casadei, Riccardo; Pacilio, CARLO ALBERTO; Ricci, Claudio; Taffurelli, Giovanni; Pagano, Nico; Santini, Donatella; Migliori, Marina; **Di Marco, Mariacristina**; Serra, Carla; Calculli, Lucia; DE GIORGIO, Roberto; Minni, Francesco, **Multicolour versus monocolour inking specimens after pancreaticoduodenectomy for periampullary cancer: A single centre prospective randomised clinical trial**, «JOP. JOURNAL OF THE PANCREAS», 2017, 2, pp. 203 - 207

2017 - Abstract

Pacilio, CARLO ALBERTO; Ricci, Claudio; Taffurelli, Giovanni; **Di Marco, Mariacristina**; Calculli, Lucia; Serra, Carla; Pagano, Nico; Santini, Donatella; Migliori, Marina; Minni, Francesco; Casadei, Riccardo, **Intraductal papillary mucinous neoplasms: the Bologna experience.**  **Lessons learned from 357 cases observed in a tertiary care center**, «PANCREATOLOGY», 2017, 17, pp. 78 - 79

2017 - Abstract

Taffurelli, Giovanni; Ricci, Claudio; Pacilio, CARLO ALBERTO; Pagano, Nico; Santini, Donatella; Migliori, Marina; **Di Marco, Mariacristina**; Serra, Carla; Calculli, Lucia; DE GIORGIO, Roberto; Minni, Francesco; Casadei, Riccardo, **Intraductal papillary mucinous neoplasms: the bologna experience.**  **Lessons learned from 357 cases observed in a tertiary care center**, «MINERVA GASTROENTEROLOGICA E DIETOLOGICA», 2017, 63, pp. 16 - 17

2017 - Article in scientific journal

Casadei, R; Ricci, C; Taffurelli, G; Pacilio, Ca; Di Marco, M; Pagano, N; Serra, C; Calculli, L; Santini, D; Minni, F., **Prospective validation of a preoperative risk score model based on pancreatic texture to predict postoperative pancreatic fistula after pancreaticoduodenectomy**, «INTERNATIONAL JOURNAL OF SURGERY», 2017, 48, pp. 189 - 194

2017 - Conference proceedings - Poster

Grassi, Elisa; Durante, Sandra; Astolfi, Annalisa; Freier, Eva; Comito, Francesca; Frega, Giorgio; Palloni, Andrea; Panzacchi, Riccardo; Santini, Donatella; Falconi, Mirella; Teti, Gabriella; Serravalle, Salvatore; Casadei, Riccardo; Ricci, Claudio; Biasco, Guido; **Di Marco, Mariacristina**, **TERC AND MYC COPY NUMBER GAIN AS POWERFUL GENETIC MARKERS FOR INTRADUCTAL PAPILLARY NEOPLASMS OF THE PANCREAS, in: TERC AND MYC COPY NUMBER GAIN AS POWERFUL GENETIC MARKERS FOR INTRADUCTAL PAPILLARY NEOPLASMS OF THE PANCREAS**, 2017(atti di: EPC 2017, BUDAPEST, 28/06/2017-01/07/2017)

2017 – Abstract

 Grassi, Elisa; Durante, Sandra; Astolfi, Annalisa; Freier, Eva; Comito, Francesca; Palloni, Andrea; Frega, Giorgio; Panzacchi, Riccardo; Santini, Donatella; Ricci, Claudio; Casadei, Riccardo; Falconi, Mirella; Teti, Gabriella; Serravalle, Salvatore; Indio, Valentina; Tarantino, Giuseppe; Biasco, Guido; **Di Marco, Mariacristina**, **TERC and c-MYC COPY number gain in intraductal papillary mucinous neoplasms (IPMNs): promising biomarkers of progression to malignancy**, «PANCREATOLOGY», 2017, 17, pp. 16 - 16

2017 - Poster

G. Giordano, G. Lo Re, M. Milella, **M. Di Marco**, D. Melisi, A. Passardi, A. Iop, A. Febbraro, L. Foltran, B. Francesca, P. Bertocchi, V. Vaccaro, M.B. Aloi, E. Giommoni, V. Ricci, E. Vasile, A. Zaniboni, V. Zagone, F. De Vita; **Nab paclitaxel (Nab-P) and gemcitabine (G) first line chemotherapy (CT) in metastatic pancreatic cancer (mPC) patients (pts) relapsed after adjuvant treatment (ADJ T): A “real life” study.** European Journal of cancer, February 2017, Volume 72, Supplement 1, Page S87

2016 – Article in scientific journal

Durante, Sandra; Vecchiarelli, Silvia; Astolfi, Annalisa; Grassi, Elisa; Casadei, Riccardo; Santini, Donatella; Panzacchi, Riccardo; Ricci, Claudio; Serravalle, Salvatore; Tarantino, Giuseppe; Falconi, Mirella; Teti, Gabriella; Indio, Valentina; Pession, Andrea; Minni, Francesco; Biasco, Guido; **Di Marco, Mariacristina**, **Copy number gain of chromosome 3q is a recurrent event in patients with intraductal papillary mucinous neoplasm (IPMN) associated with disease progression**, «ONCOTARGET», 2016, 7, pp. 74797 - 74806

2016 – Article in scientific journal

Mr Brandi, John; Deserts, Martians; Vasuri, Francis; Farioli, Andrea; Degiovanni, Alexios; Palloni, Andrea; Frigate, George; Barbera, Maria A; De Lorenzo, Stefania; Garajova, Ingrid; **Di Marco, Mariacristina;** Pinna, Antonio D; Cescon, Matthew; Cucchetti, Alessandro; Herculaneums, George; D'Errico-Graubünden, Antoinette; Pantaleus, Mary A; Biasco, Guido; Tavolari, Simona, *In Reply*, «THE ONCOLOGIST», 2016, 21, pp. e5 - e6

2016 – Article in scientific journal

Ricci Claudio, Casadei Riccardo, Taffurelli Giovanni, Zani Elia, Pagano Nico, Pacilio Carlo Alberto, Ingaldi Carlo, Bogoni Selene, Santini Donatella, Migliori Marina, **Di Marco Mariacristina**, Serra Carla, Calculli Lucia, de Giorgio Roberto, Minni Francesco (2016). **Risk Factors for Malignancy of Branch-Duct Intraductal Papillary Mucinous Neoplasms: A Critical Evaluation of the Fukuoka Guidelines with a Systematic Review and Meta-analysis**. PANCREAS, vol. Epub ahead of print, p. 1-10, ISSN: 0885-3177, doi: 10.1097/MPA.0000000000000642

2016 – Article in scientific journal

**MARIACRISTINA DI MARCO**, ELISA GRASSI, SILVIA VECCHIARELLI, SANDRA DURANTE, MARINA MACCHINI and GUIDO BIASCO **Retroperitoneal lymphangioma: A report of 2 cases and a review of the literature regarding the differential diagnoses of retroperitoneal cystic masses** ONCOLOGY LETTERS 11: 3161-3166, 2016

2016 – Article in scientific journal

Brandi Giovanni, Deserti Marzia, Vasuri Francesco, Farioli Andrea, Degiovanni Alessio, Palloni Andrea, Frega Giorgio, Barbera Maria A., De Lorenzo Stefania, Garajova Ingrid, Di Marco Mariacristina, Pinna Antonio D., Cescon Matteo, Cucchetti Alessandro, Ercolani Giorgio, D’errico-Grigioni Antonietta, Pantaleo Maria A., Biasco Guido, Tavolari Simona (2016). **Membrane localization of human equilibrative nucleoside transporter 1 in tumor cells may predict response to adjuvant gemcitabine in resected cholangiocarcinoma patients**. THE ONCOLOGIST, vol. 21, p. 600-607, ISSN: 1083-7159, doi: 10.1634/theoncologist.2015-0356

2016 – Article in scientific journal

Casadei Riccardo, Ricci Claudio, Taffurelli Giovanni, Guariniello Anna, Di Gioia Anthony, **Di Marco Mariacristina**, Pagano Nico, Serra Carla, Calculli Lucia, Santini Donatella, Minni Francesco (2016).  **Is total pancreatectomy as feasible, safe, efficacious, and cost-effective as pancreaticoduodenectomy? A single center, prospective, observational study**. JOURNAL OF GASTROINTESTINAL SURGERY, vol. 20, p. 1595-1607, ISSN: 1091-255X, doi: 10.1007/s11605-016-3201-4

2016 – Article in scientific journal

**M. DI MARCO**, E. GRASSI, S. VECCHIARELLI, S. DURANTE, M. MACCHINI and G. BIASCO **Retroperitoneal lymphangioma: A report of 2 cases and a review of the literature regarding the differential diagnoses of retroperitoneal cystic masses**, pag 1-6, Marzo 2016 , Oncology letters

2016 – Article in scientific journal

**Di Marco M**, Grassi E, Durante S, Vecchiarelli S, Palloni A, Macchini M, Casadei R, Ricci C, Panzacchi R, Santini D, Biasco G.  **State of the art biological therapies in pancreatic cancer**. World J Gastrointest Oncol. 2016 Jan 15;8(1):55-66. doi: 10.4251/wjgo.v8.i1.55. Review.

2016 – Abstract

Guido Giordano, Antonio Febbraro, Michele Milella, Vanja Vaccaro, Davide Melisi, Luisa Foltran, Vittorina Zagonel, Alberto Zaniboni, Paola Bertocchi, Francesca Bergamo, Alessandro Passardi, Gianna Musettini, Elisa Giommoni, Aldo Iop, Maria Bernardetta Aloi, Silvia Vecchiarelli, Enrico Vasile, Giovanni Lo Re, **Mariacristina Di Marco**, Ferdinando De Vita;  **Impact of second-line treatment (2L T) in advanced pancreatic cancer (APDAC) patients (pts) receiving first line Nab-Paclitaxel (nab-P) + Gemcitabine (G): an Italian multicenter real life experience.** J Clin Oncol 34, 2016 (suppl; abstr 4124)

2015 – Book co-author

Follow up in Oncology, From Clinical Practice to Evidence, Cost/Effectiveness, author G. Brandi, Bononia University Press, September 25, 2015.

2015 – Article in scientific journal

**Di Marco M**, Astolfi A, Grassi E, Vecchiarelli S, Macchini M, Indio V, Casadei R, Ricci C, D'Ambra M, Taffurelli G, Serra C, Ercolani G, Santini D, D'Errico A, Pinna AD, Minni F, Durante S, Martella LR, Biasco G.  **Characterization of pancreatic ductal adenocarcinoma using whole transcriptome sequencing and copy number analisys by single-nucleotide polymorphism array**. **Molecular Medicine Reports**, Vol. 12 p. 7479-7484, ISSN 1791-2997, doi: 10.3892/mmr. **2015**.4344

2015 – Poster e abstract

**Mariacristina Di Marco**, Sandra Durante, Silvia Vecchiarelli, Elisa Grassi, Andrea Palloni, Valentina Indio, Annalisa Astolfi, Chiara Giusy Genovese, Riccardo Panzacchi, Donatella Santini, Riccardo Casadei, Claudio Ricci, Giorgio Ercolani, Nicola Pagano, Lucia Calculli, Carla Serra, Francesco Minni, Antonio Daniele Pinna, Guido Biasco (2015).  **Discovery of new potentially actionable mutations in pancreatic ductal adenocarcinoma by next generation sequencing**. PANCREATOLOGY, vol. 15, p. 49, ISSN: 1424-3903

2015 - Poster

**Mariacristina Di Marco et al.**

**Discovery of new potentially actionable mutations in pancreatic ductal adenocarcinoma by next generation sequencing. ASCO Meetings, Chicago, 2015.**

2015 – Article in scientific journal

Casadei R, **Di Marco M**, Ricci C, Santini D, Serra C, Calculli L, D'Ambra M, Guido A, Moreselli-L'Abate AM, Minni F.  **Neoadjuvant chemoradiotherapy and surgery versus surgery alone in resectable pancreatic cancer: a single-center prospective, randomized, controlled trial which failed to achieve accrual targets. Journal of gastrointestinal surgery**, Vol. I, p. 1 ISSN 1091-255X, DOI: 10.1007/S 11605 - 015-2890-4 **2015**

2015 – Article in scientific journal

Ricci C, Casadei R, Taffurelli G, Toscano F, Pacilio CA, Bogoni S, D'Ambra M, Pagano N, **Di Marco MC**, Minni F.  **Laparoscopic versus open distal pancreatectomy for ductal adenocarcinoma: a systematic review and meta-analysis. J Gastrointest Surg. 2015** Apr;19(4):770-81. doi: 10.1007/s11605-014-2721-z. Epub**2015** Jan 6.

2015 – Article in scientific journal

Fuccio L, Correale L, Arezzo A, Repici A, Manes G, Trovato C, Mangiavillano B, Manno M, Cortelezzi CC, Dinelli M, Cennamo V, de Bellis M, **M Di Marc**o, KRASTENT Study Group.  **Influence of K-ras status and anti-tumour treatments on complications due to colorectal self-expandable metallic stents: a retrospective multicenter study**.  **Dig Liver Dis. 2014**Jun;46(6):561-7. doi: 10.1016/j.dld.2014.02.006. Epub**2014** Mar 14.

2014 - Article in scientific journal

Brandi G, Tavolari S, Guarnieri T, **Di Marco M**, Paterini P, Macchini M, Di Girolamo S, Papi A, De Rosa F, Biasco G (2013). **Antiprotease Strategy in Pancreatic Cancer Treatment Emergences from Preclinical**. PANCREAS, ISSN: 0885-3177

2013 - Poster

Marina Macchini, Annalisa Astolfi, Valentina Indio, Silvia Vecchiarelli, Elisa Grassi, Carla Serra, Riccardo Casadei, Donatella Santini, Marielda D'Ambra, Claudio Ricci, Francesco Minni, Guido Biasco, **Mariacristina Di Marco** (2013). **Whole-transcriptome paired-end sequencing and the pancreatic cancer genetic landscape**. In: J Clin Oncol 31, 2013 (suppl; abstr 4048). p. 4048, Chicago, 31 maggio-04 giugno 2013

2013 - Poster

Marina Macchini, Annalisa Astolfi, Riccardo Casadei, Valentina Indio, Carla Serra, Silvia Vecchiarelli, Elisa Grassi, Claudio Ricci, Marielda D'Ambra, Giovanni Taffurelli, Donatella Santini, Raffaele Pezzilli, Francesco Minni, Guido Biasco, **Mariacristina Di Marco** (2013). **Whole genome discovery of genetic alterations carried by pancreatic adenocarcinoma**. In: AACR American Association for Cancer Research. p. 812, Washington, 6-10 aprile 2013

Abstract in Conference Proceedings (2013)

32. Vecchiarelli S, Macchini M, Grassi E, Ferroni F, Ciccarese F, Calculli L, Ricci C, Casadei R, Pezzilli R, Biasco G, **Di Marco M** (2013). **Comparing recist and Choi’s criteria to evaluate radiological response to chemotherapy in patients with advanced pancreatic cancer.** In: Proceedings ASCO Journal of Clinical Oncology. vol. 31, J Clin Oncol, Chicago, Illinois, May 31-June 4, 2013

Abstract in Conference Proceedings (2013)

**Di Marco M**, Zingaretti CC, Ricci C, Vecchiarelli S, Taffurelli G, Macchini M, D’Ambra M, Buscemi S, Monari F, Casadei R, Biasco G, Minni F (2013). **Locally advanced pancreatic cancer: is it possible pancreatic resection? Case report**. In: JOP. journal of pancreas, Bologna, 19-21/09/2013

Abstract in Conference Proceedings (2013)

Vecchiarelli S, Macchini M, Astolfi A, Indio V, Grassi E, Casadei R, Martella L.R, Ercolani G, Serra C, Santini D, D’Errico A, Pinna A.D., Minni F, Biasco G, **Di Marco M** (2013). **Whole transcriptome sequencing reveals molecular prognostic markers in pancreatic adenocarcinoma**. In: JOP. journal of pancreas, Bologna, 19-21/09/2013

Abstract in Conference Proceedings (2013)

Vecchiarelli S, Macchini M, Astolfi A, Indio V, Grassi E, Martella L.R, Casadei R, Serra C, Santini D, Pezzilli R, Minni F, Biasco G, **Di Marco M** (2013). **Whole transcriptome sequencing reveals somatic HMGCR mutation in a case of pancreatic adenocarcinoma with long-term therapy response.** In: JOP. journal of pancreas, Bologna, 19-21 Sept 2013

Abstract in Conference Proceedings (2013)

Macchini M, Astolfi A, Indio V, Vecchiarelli S, Grassi E, Casadei R, Verlicchi L, Santini D, Minni F, Biasco G, **Di Marco M** (2013). **A novel somatic alteration involving the HMGCR gene in a patient affected by locally advanced pancreatic cancer**. In: I Supplementi di Tumori. Milano, 11-12-13 Ottobre 2013

Abstract in Conference Proceedings (2013)

**By Marco M**, Astolfi A, Indio V, Macchini M, Vecchiarelli S, Grassi E, Casadei R, Serra C, Ercolani G, Santini D, D'Errico A, Pinna AD, Minni F, Biasco G (2013). **Characterization of pancreatic ductal adenocarcinoma patients using whole-transcriptome sequencing**. In: Tumor Supplements. Milan, 11-12-13 October 2013

2012 - Article in scientific journal

M. **Di Marco, M**. Macchini, S. Vecchiarelli, S. Sina, G. Biasco (2012). **Hedgehog Signaling: from the Cuirass to the Heart of Pancreatic Cancer**. PANCREATOLOGY, vol. 12 (4), p. 388-393, ISSN: 1424-3903

2012 - Article in scientific journal

M. Di Marco, S. Vecchiarelli, M. Macchini, R. Pezzilli, D. Santini, R. Casadei, L. Calculli, S. Sina, R. Panzacchi, C. Ricci, E. Grassi, F. Minni, G. Biasco (2012). **Preoperatory Gemcitabine and Oxaliplatin in a patient with ovarian metastasis from pancreatic cystadenocarcinoma**. CASE REPORTS IN GASTROENTEROLOGY, vol. 6 (2), p. 530-537, ISSN: 1662-0631

Abstract in Conference Proceedings (2012)

M. Macchini, A. Astolfi, R. Casadei, V. Indio, S. Vecchiarelli, C. Ricci, M. Di Marco (2012). **Massively Parallel Sequencing Analysis of Genetic Alterations Carried by Pancreatic Adenocarcinoma**. In: JOP. journal of pancreas, vol. 13 (5S), p. 620, ISSN: 1590-8577, Bologna, 4-6 Ottobre 2012

Abstract in Conference Proceedings (2012)

S. Buscemi, G. Taffurelli, M. D’Ambra, F. Monari, M. Macchini, C. Ricci, M. Di Marco (2012). **Resection Margin Involvement in Pancreaticoduodenectomy.A Single Centre Experience**. In: JOP. journal of pancreas, vol. 13 (5S), p. 590, ISSN: 1590-8577, Bologna, 4-6 Ottobre 2012

Abstract in Conference Proceedings (2012)

M.Macchini, A. Astolfi, R. Casadei, C. Ricci, V. Indio, S. Vecchiarelli, M. Di Marco (2012). **SNP-Array High Resolution Cytogenetic Analysis of Resectable and Advanced Pancreatic Cancer**. In: JOP. journal of pancreas, vol. 13 (5S), p. 619, ISSN: 1590-8577, Bologna, 4-6 Ottobre 2012

Abstract in Conference Proceedings (2012)

S. Vecchiarelli, M. Macchini, C. Ricci, M. D'Ambra, R. Casadei, L. Calculli, M. Di Marco (2012). **Comparing RECIST and Choi’s Criteria to Evaluate Radiological Response to Chemotherapy in Patients with Advanced Pancreatic Cancer.** In: JOP. journal of pancreas, vol. 13 (5S), p. 578, ISSN: 1590-8577, Bologna, 4-6 Ottobre 2012

Abstract in Conference Proceedings (2012)

Macchini M., Ricci C., Vecchiarelli S., D’Ambra M., Casadei R., Calculli L., Pezzilli R., Grassi E., Minni F., Biasco G., **Di Marco M**. (2012). **Comparing RECIST and Choi’s Criteria to Evaluate Radiological Response to Chemotherapy in Patients with Resectable and Advanced Pancreatic Cancer.** In: TUMORI. I SUPPLEMENTI DI TUMORI, vol. 13, number 3, p. S16 - A30, Roma, 27-29 ottobre 2012

Abstract in Conference Proceedings (2012)

M Macchini, G Brandi, S Tavolari, T Guarnieri, **M Di Marco**, P Paterini, F De Rosa, S Di Girolamo, S Vecchiarelli, A Papi, G Biasco (2012). **Antiprotease strategy in combination with gemcitabine as a putative novel therapeutic approach for pancreatic cancer treatment.** In: (a cura di): /, pancreatology. PANCREATOLOGY, vol. 12, p. 506, Amsterdam: Academic Press (Elsevier), ISSN: 1424-3903, Praga, 20-23/06/2012, doi: 10.1016/j.pan.2012.11.015

Abstract in Conference Proceedings (2012)

MACCHINI M., Ricci C., VECCHIARELLI S., D’Ambra M., CASADEI R., CALCULLI L., Pezzilli R., Grassi E., MINNI F., BIASCO G., **DI MARCO M.** (2012). **Comparing RECIST and Choi’s Criteria to Evaluate Radiological Response to Chemotherapy in Patients with Resectable and Advanced Pancreatic Cancer.** In: JOP. journal of pancreas. vol. 13, p. S16, Roma, 27-29 ottobre 2012

Abstract in Conference Proceedings (2012)

Machini M, Astolfi A, Casadei R, Ricci C, Indio V, Vecchiarelli S, D'Ambra M, Grassi E, Santini D, Minni F, Biasco G, **Di Marco M** (2012). **Whole genome discovery of genetic alterations in resectable and advanced pancreatic cancer**. In: (edited by): PROF. STEFANO CASCINU, TUMORS. TUMOR SUPPLEMENTS, vol. vol.13, num 3, p. S14, Rome, 27-29 October

2011 - Article in scientific journal

**M.Di Marco**, M.Macchini, S.Vecchiarelli, R.Casadei, R.Pezzilli, S.Fanti, L.Zanoni, L.Calculli, E. Barbieri, D.Santini, R.Di Cicilia, G.Brandi, G.Biasco (2011). **Chemotherapy followed by chemoradiotherapy in locally advanced pancreatic cancers: A literature review and report of two cases.**  ONCOLOGY LETTERS, vol. 2, num.2, p. 195-200, ISSN: 1792-1074

2011 - Article in scientific journal

Pezzilli R, Vecchiarelli S, **Di Marco MC**, Serra C, Santini D, Calculli L, Fabbri D, Rojas Mena B, Imbrogno A. SourcePancreas Unit, Department of Digestive Diseases and Internal Medicine, University of Bologna, Bologna, Italy. (2011). **Pancreatic ductal adenocarcinoma associated with autoimmune pancreatitis.** CASE REPORTS IN GASTROENTEROLOGY, vol. 5, p. 378-385, ISSN: 1662-0631

Abstract in Conference Proceedings (2011)

Vecchiarelli S, Macchini M, **Di Marco M**, Pezzilli R, Fabbri D, Imbrogno A, Casadei R, Melzi d’Eril G, Sina S, Biasco G (2011). **CIRCULATING METALLOPROTEINASE-3 AND TISSUE INHIBITOR OF METALLOPROTEINASE-2 IN PATIENTS WITH DUCTAL PANCREATIC NEOPLASMS**. In: TUMORI. I SUPPLEMENTI DI TUMORI, vol. 11, p. S46, BOLOGNA, 05/11/2011- 07/11/2011

Abstract in Conference Proceedings (2011)

**Di Marco M**, Macchini M, Ricci C, Taffurelli G, D'Ambra M, Vecchiarelli S, Pallotti MC, Pezzilli R, Martoni AA, Casadei R, Biasco G (2011). **Prognostic factors for recurrence in resected pancreatic adenocarcinoma: a single center experience**. In: JOP. journal of pancreas, vol. 29, p. e14541, ISSN: 0732-183X, Chicago, Giugno 2011

Abstract in Conference Proceedings (2011)

Monari F, D'Ambra M, Ricci C, Buscemi S, Calculli L, Pezzilli R, Santini D, **Di Marco MC**, Macchini M, Casadei R, Minni F (2011). **Comparing RECIST and Choi's Criteria After Neoadjuvant Chemoradiotherapy in Patients with Resectable Pancreatic Cancer.** In: JOP. journal of pancreas, vol. 12, p. 515-516, ISSN: 1590-8577, Peschiera del Garda, 13/10/2011- 15/10/2011

Abstract in Conference Proceedings (2011)

Macchini M, Vecchiarelli S, Sina S, Ricci C, Casadei R, Pezzilli R, Calculli L, Santini D, Biasco G, **Di Marco M** (2011). Role of CA 19-9 **Concentration as an Independent Prognostic Factor in Unresectable Pancreatic Ductal Adenocarcinoma (PDCA) Treated with GemOx**. In: JOP. journal of pancreas, vol. 12, p. 537, ISSN: 1590-8577, Peschiera del Garda, 13/10/2011- 15/10/2011

2010 - Article in scientific journal

**M. Di Marco**, R. Di Cicilia, M. Macchini, E. Nobili, S. Vecchiarelli, G. Brandi, G. Biasco (2010). **Metastatic pancreatic cancer: is gemcitabine still the best standard treatment?** (Review). ONCOLOGY REPORTS, vol. 23(5), p. 1183-1192, ISSN: 1021-335X, doi: 10.3892/or\_00000749

2010 - Contribution to Conference Proceedings

PALLOTTI MC, VECCHIARELLI S, MACCHINI M, **DI MARCO M**, D’AMBRA M, FERRONI F, POLI F, CALCULLI L, MINNI F, CASADEI R, SANTINI D, BIASCO G (2010). **GemOx and Ovarian Pancreatic Cancer Metastasis (PC). In: AISP - 34th National Congress.** In: JOP. journal of pancreas, vol. 11 (5 suppl), p. 530-531, ISSN: 1590-8577, Peschiera del Garda, VR (Italy)., October 7-9, 2010

2010 - Contribution to Conference Proceedings

**M.DI MARCO,** M. MACCHINI, M D'AMBRA, C. RICCI, S. VECCHIARELLI, M.C. PALLOTTI, B. MELOTTI, F. SPERANDI, R. PEZZILLI, L. CALCULLI, D. SANTINI, E. BARBIERI, C. SERRA, R. CASADEI, F. MINNI, A.A. MARTONI, G. BIASCO (2010). **Prognostic factors in resected pancreatic cancer: a single centre experience.** In: XII national Congress of Medical Oncology. I SUPPLEMENTI DI TUMORI, vol. 10, num.1, p. 152-153, Roma, 6-8 Novembre 2010

Abstract in Conference Proceedings (2010)

**M. Di Marco,** M. Macchini, R. di Cicilia, S. Vecchiarelli, R. Casadei, E. Barbieri, L. Calculli, M. A. Pantaleo, G. Biasco (2010). **Neoadjuvant therapy for resectable pancreatic adenocarcinoma: An interim report of a prospective randomized study**. In: JOURNAL OF CLINICAL ONCOLOGY, vol. 28 (suppl; abstr e14604), ISSN: 0732-183X

Abstract in Conference Proceedings (2010)

Macchini M1, Vecchiarelli S, **Di Marco M**, D’Ambra M, Ricci C, Pallotti MC, Melotti B, Sperandi F, Pezzilli R, Calculli L, Santini D, Barbieri E, Serra C, Casadei R, Minni F, Martoni AA, Biasco G (2010). **Risk Factors in Resected Pancreatic Cancer.A Single Centre Experience**. In: JOP. journal of pancreas, vol. 11 (5 suppl), p. 527, ISSN: 1590-8577, Peschiera del Garda, VR (Italy)., October 7-9, 2010

Abstract in Conference Proceedings (2010)

Buscemi S, Laterza M, Monari F, D’ambra M, Alagna V, Rega D, Ricci C, Taffurelli G, Pezzilli R, **Di Marco M**, Macchini M, Calculli L, Santini D, Casadei R, Minni F (2010). **Long-Term Survival After Pancreaticoduodenectomy for Pancreatic Ductal Adenocarcinoma. Case Report.** In: JOP. journal of pancreas, vol. 11 (5 suppl), p. 521-522, ISSN: 1590-8577, Peschiera del Garda, VR (Italy)., October 7-9, 2010

Abstract in Conference Proceedings (2010)

Macchini M, Brandi G, Tavolari S, Guarnieri T, de Rosa F, Paterini P, Di Girolamo S, Agostini V, **Di Marco M**, Vecchiarelli S, Di Cicilia R, Nobili E, Biasco G. (2010). **The Protease Inhibitor Gabexate Mesylate Reduces Invasiveness and Angiogenesis in Pancreatic Cancer Cell Lines, Enhancing Gemcitabine Action.** In: JOP. journal of pancreas, vol. 11 (5 suppl), p. 512, ISSN: 1590-8577, Peschiera del Garda, VR (Italy)., October 7-9, 2010

2009 - Contribution in volume (Chapter or Essay)

Biasco, G., M Di Battista, **M.C. DI Marco** (2009). Duodenum tumors. In: (edited by): PROF. G. GASBARRINI, A MORELLI, Extract **from treatise on Internal Medicine; Volume VIII, Diseases of the Digesting Canal.** p. 605-609, PADOVA: Piccin Nuova Libreria, ISBN: 978-88-299-1996-3

Abstract in Conference Proceedings (2009)

Brandi G, tavolari S, Paterini P, de Rosa F, Di Girolamo S, Agostini V, Di Cicilia R, **Di Marco M**, Nobili E, Biasco G. (2009). **The protease inhibitor gabexate Mesylate has antitumor effects and enhances gemcitabine action on pancreatic cancer cell lines.** In: 11 National Congress of medical Oncology 10-13 October Milan, Italy. ANNALS OF ONCOLOGY, vol. 20, supplemento 8, p. 151, ISSN: 0923-7534, Milano, 10-13 Ottobre 2009

2009 - Contribution to Conference Proceedings

**DI MARCO M**, MACCHINI M, DI CICILIA R, NOBILI E, BIASCO G. (2009). **Advanced pancreatic cancer (APC) A monocenter experience in 53 patients: is it possible a second line treatment?** In: 11 National Congress of medical Oncology. ANNALS OF ONCOLOGY, vol. 20, p. 164, ISSN: 0923-7534, Milano, 10-13 Ottobre 2009

2009 - Contribution to Conference Proceedings

DI MARCO M, MACCHINI M, DI CICILIA R, NOBILI E, BIASCO G. (2009). **Advanced pancreatic cancer (apc); a Monocenter experience in 53 patients. It is possible a second line treatment?** In: 33 Congresso AISP. JOP. JOURNAL OF THE PANCREAS, vol. 10, p. 596-597, ISSN: 1590-8577, Rozzano (MI), 15-17 Ottobre 2009

2009 - Contribution to Conference Proceedings

D'AMBRA M, CASADEI R, PEZZILLI R, CALCULLI L, BARBIERI E, **DI MARCO M**, REGA D, RICCI C, MACCHINI M, ANGELELLI B, SERRA C, BRUNO A, LEGA S, SANTINI D, MINNI F. (2009). **Neoadjuvant therapy for resectable pancreatic adenocarcinoma: an interim report of a prospective controlled randomized study.** In: 33 Congresso AISP. JOP. JOURNAL OF THE PANCREAS, vol. 10, p. 595, ISSN: 1590-8577, Rozzano (MI), 15-17 Ottobre 2009

Abstract in Conference Proceedings (2009)

G. Brandi, P. Paterini, S. Tavolari, G. dal Pozzo, E. Nobili, R. Di Cicilia, **M. Di Marco**, M. Pantaleo, F. de Rosa, G. Biasco (2009). **Effect of serine proteases inhibitor gabexate mesylate (GM) on the activity of gemcitabine (G) in cell lines of pancreatic cancer**. In: ASCO annuals meeting 2009. JOURNAL OF CLINICAL ONCOLOGY, vol. 27,15S, e15645, p. 280, ISSN: 0732-183X, Orlando, 29 maggio 3giugno

Abstract in Conference Proceedings (2009)

Macchini M, Di Cicilia R, Vecchiarelli S, de Rosa F, Nobili E, **Di Marco M**, Biasco G. (2009). **Role of adjuvant chemoradiotherapy (CRT) and chemotherapy alone in pancreatic cancer: experience in 25 patients.** In: JOP. JOURNAL OF THE PANCREAS. JOP. JOURNAL OF THE PANCREAS, vol. 10, p. 618-619, ISSN: 1590-8577,

Abstract in scientific journal (2009)

G. Brandi, P. Paterini, S. Tavolari, G. dal Pozzo, E. Nobili, R.Di Cicilia, **M. Di Marco**, MA. Pantaleo, F. De Rosa, G. Biasco (2009). **Effect of serine proteases inhibitor gabexate mesylate (GM) on the activity of gemcitabine (G) in cell lines of pancreatic cancer**. JOURNAL OF CLINICAL ONCOLOGY, vol. 27, p. 280, ISSN: 0732-183X

2008 - Article in scientific journal

G. BRANDI, E. NOBILI, E. CAPIZZI, B. CORTI, R. DI CICILIA, **M. DI MARCO**, G. BIASCO (2008).  **EXOCRINE-ENDOCRINE PANCREATIC CANCER AND alpha-FETOPROTEIN. PANCREAS**, vol. 37 num.2, p. 223-225, ISSN: 0885-3177

2008 - Contribution to Conference Proceedings

**M.DI MARCO**, M. MACCHINI, R. DI CICILIA, E. NOBILI, G. BIASCO (2008). **GEMOX AS FIRST-LINE CHEMOTHERAPY IN ADVANCED PANCREATIC CANCER (APC): A MONOINSTITUTIONAL EXPERIENCE.** In: JOP J Pancreas (Online) .vol. 9(6 suppl), p. 804-805, Montecatini, October 2-4 2008

2008 - Contribution to Conference Proceedings

R. DI CICILIA, M. MACCHINI, M. DI MARCO, E. NOBILI, L. CALCULLI, R. CASADEI, G. BIASCO (2008). **GEMOX IN COMBINATION WITH ERLOTINIB (E) IN PANCREATIC CANCER (PC).** In: JOP J Pancreas (Online) . vol. 9 (6 Suppl) :, Montecatini Terme (PT), October 02-04, 2008

Abstract in Conference Proceedings (2008)

G. Brandi, R Di Cicilia, M. Di Battista, E. Nobili, M. Astorino, **M. Di Marco**, MA Pantaleo, G. Biasco (2008). **Capecitabine (CAP) based regimens vs infusional 5FU/AF in metastatic colorectal cancer cost/effectivness: the differences across the atlantic ocean.** In: 10 National congress of Medical Oncology. ANNALS OF ONCOLOGY, vol. 19 (Suppl.9), p. ix132, ISSN: 0923-7534, Verona, 11-14 october 2008

Abstract in Conference Proceedings (2007)

**Di Marco M**, Nobili E, Di Cicilia R, Brandi G, Bertolini S, Derenzini E, Dell’Arte S, Casadei R, Calculli L, Biasco G. (2007). **GEMOX AS FIRST-LINE CHEMOTHERAPY IN ADVANCED PANCREATIC CANCER (APC): A MONOISTITUTIONAL EXPERIENCE.** In: american society of clinical oncology. 43rd annual meeting. JOURNAL OF CLINICAL ONCOLOGY, vol. 25, p. 727, ISSN: 0732-183X, chicago, illinois, 1-5 giugno 2007

2006 - Article in scientific journal

DERENZINI E, DI BATTISTA M, **DI MARCO MC,** DELL'ARTE S, ASTORINO M, BERTOLINI S, BRANDI G, BIASCO G. (2006). **Treatment of colorectal cancer liver metastases.** MINERVA MEDICA, vol. 97, p. 107-119, ISSN: 0026-4806

2006 - Contribution to Conference Proceedings

**MC DI MARCO**, R. DI CECILIA, M. DI BATTISTA, E. PALMERINI, E. DERENZINI, R. POGGI, S. FANELLO, M. ASTORINO, G. BIASCO (2006). **Effect of folate anc alphalipoic acid supplementation on rectal mucosal cells kinetics.** In: 2006 World Congress on Gastrointestinal cancer. ANNALS OF ONCOLOGY, vol. 17, p. 69, ISSN: 0923-7534, Barcellona, 28/06/2006

2006 - Contribution to Conference Proceedings

N. ZANINI, R. CASADEI, B. ANGELELLI, **MC DI MARCO**, C. SERRA, L. PISCITELLI, F. MINNI (2006). **Locally Advanced Pancreatic Cancer: Is There a Role for Neoadjuvant Chemo-Radiation? A Case Report and Literature Review**. In: JOP. J Pancreas (Online).vol. 7(5 Suppl), p. 553-554, Milano, September 21-23, 2006

2005 - Contribution to Conference Proceedings

V. SCURTI, D. SICHETTI, M. ROMERO, ETEO WORKING GROUP (…, **MC DI MARCO**, …) (2005). **Prospective, multicenter, observational analysis of 5-HT3 receptor antagonist antiemetic prescribing with different chemotherapy regiments.** In: ASCO 2005. JOURNAL OF CLINICAL ONCOLOGY, vol. 16S Pat I of II, p. 791s, ISSN: 0732-183X, Orlando, 13/05/2005

2005 - Contribution to Conference Proceedings

M. DI BATTISTA, G. BRANDI, S. DELL’ARTE, MA PANTALEO, S. FANELLO, E. DERENZINI, M. ASTORINO, R. POGGI, **MC DI MARCO**, M. PIRAZZINI, V. NAPPI, G. ALTIMARI, S. BARONCINI, G. BIASCO (2005). **Cost of management of completely implantable catheters (CIC) in patients treated for advanced colorectal cancer.** In: VII National Congress of Medical Oncology. ANNALS OF ONCOLOGY, vol. 16, p. 41, ISSN: 0923-7534, Napoli, 18/10/2005

2005 - Contribution to Conference Proceedings

G. BRANDI, E. DERENZINI, E. NOBILI, **MC DI MARCO**, MA PANTALEO, E. PALASSINI, S. DELL’ARTE, R. HAKIM, M. DI BATTISTA, S. FANELLO, GL GRAZI, A. CAVALLARI, G. BIASCO (2005). **Impact of surgery and Chemotherapy on survival in cholangiocarcinoma.** In: VII National Congress of Medical Oncology. ANNALS OF ONCOLOGY, vol. 16, p. 50, ISSN: 0923-7534, Napoli, 18/10/2005

2005 - Article in scientific journal

G Biasco, MC. Di Marco (2005). **Folate and prevention of colorectal cancer in ulcerative colitis.**  EUROPEAN JOURNAL OF CANCER PREVENTION, vol. 14(4):, p. 395-398, ISSN: 0959-8278, doi: 10.1097/00008469-200508000-00013

2004 - Article in scientific journal

BRANDI G, CALABRESE C, PANTALEO MA, MORSELLI LABATE A, DI FEBO G, HAKIM R, DE VIVO A, **DI MARCO MC**, BIASCO G. (2004). **Circadian variations of rectal cell proliferation in patients affected by advanced colorectal cancer.** CANCER LETTERS, vol. 208 (2), p. 193-196, ISSN: 0304-3835, doi: 10.1016/j.canlet.2003.11.015

2004 - Contribution to Conference Proceedings

M.A. PANTALEO, G. BRANDI, E. DERENZINI, S. FANELLO, **MC DI MARCO**, M. DI BATTISTA, E. NOBILI, G. BIASCO (2004). **Is adjuvant systemic chemotherapy after resection of metastases from colorectal cancer suitable?** In: ASCO 2004. JOURNAL OF CLINICAL ONCOLOGY, vol. 23, p. 283, ISSN: 0732-183X, New Orleans, 05/06/2004

2004 - Contribution to Conference Proceedings

G. BRANDI, E. DERENZINI, M.A. PANTALEO, M. DI BATTISTA, M. RAVAIOLI, G. ERCOLANI, G.L. GRAZI, S. FANELLO, **MC DI MARCO**, E. NOBILI, R. HAKIM, R. POGGI, E. PALMERINI, G. BIASCO (2004). **Systemic adjuvant chemotherapy after resection of colorectal cancer metastasis.** In: 6th National Congress of Medical Oncology. ANNALS OF ONCOLOGY, vol. 15, p. 66, ISSN: 0923-7534, Bologna, 21/09/2004

2004 - Article in scientific journal

R. Ridolfi, A. Romanini, V. Chiarion Sileni, M. Michiara, M. Guida, G. Biasco, P. Poletti, L. Amaducci, M. Leoni, A. Ravaioli, the Italian Melanoma Intergroup (L. Ridolfi, L. Fiammenghi, L. Ballardini, L. Tanganelli, R. Todeschini, R. Redelotti, V. Lorusso, **MC Di Marco**, R. Labianca) (2004). **Temozolomide and interferon-alpha in metastatic melanoma: a phase II study on the Italian Melanoma Intergroup.**  MELANOMA RESEARCH, vol. 14(4), p. 295-299, ISSN: 0960-8931, doi: 10.1097/01.cmr.0000136711.75287.55

Abstract in scientific journal (2004)

Brandi G, Derenzini E, Pantaleo MA, Di Battista M, Ravaioli M, Ercolani G, Grazi GL, Fanello S, **Di Marco M**, Nobili E, Hakim R, Poggi R, Palmerini E (2004). **Systemic adjuvant chemotherapy after resection of colorectal cancer metastases.**  ANNALS OF ONCOLOGY, vol. 15, p. 66, ISSN: 0923-7534

2003 - Article in scientific journal

Biasco G, **Di Marco M**, Pantaleo MA (2003). **Chemoprevention of colorectal cancer.** THE INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS, vol. 18, p. 75-77, ISSN: 0393-6155

2003 - Article in scientific journal

Biasco G, **Di Marco M**, Nobili E(2003). **Is oral therapy a real plus?** TUMOR SUPPLEMENTS, vol. 2, p. 136-138

2003 - Article in scientific journal

Brandi G, Pantaleo MA, Galli C, Falcone A, Antonuzzo A, Mordenti P, **Di Marco M**, Biasco G (2003). **Hypersensitivity reactions related to oxaliplatin (OHP)**. BRITISH JOURNAL OF CANCER, vol. 89, p. 477-481, ISSN: 0007-0920

2003 - Contribution to Conference Proceedings

Biasco G, Brandi G, Calabrese C, Pantaleo MA, Morselli Labate A, Di Febo G, **Di Marco M**, Akim R, De Vivo A (2003). **Circadian variations of rectal cell proliferation in patients affected by metastatic colorectal cancer.** In: JOURNAL OF TUMOR MARKER ONCOLOGY. JOURNAL OF TUMOR MARKER ONCOLOGY, vol. 18, ISSN: 0886-3849

Abstract in to Conference Proceedings (2002)

Pantaleo MA, Brandi G, Nobili E, Cenacchi G, Calabrese C, Di Battista M, **Di Marco M**, Biasco G (2002). **Biomolecular and phenotypic alterations of the duodenal mucosa and fap patients.** In: 1st National Congress College of University Medical Oncologists. Castiglion della Pescaia (GR), 10-11 May 2002

Abstract in to Conference Proceedings (2002)

Brandi G, Di Battista M, Dabard J, Pantaleo MA, Nobili E, **Di Marco M,** Hakim R, Biasco G (2002). **Role of bacterial flora in CPT-11 toxicity.** In: 1st National Congress College of University Medical Oncologists. Castiglion della Pescaia (GR), 10-11 May 2002, p. 78-79

2001 - Contribution to Conference Proceedings

Mordenti P, **Di Marco M**, Pantaleo MA, Gallerani E, Brandi G, Di Battista M, Biasco G (2001). **The Folfox-4 regimen: a mono institutional experience in advanced colo-rectal cancer (ACC).** In: ANNALS OF ONCOLOGY. ANNALS OF ONCOLOGY, vol. 12, ISSN: 0923-7534

2001 - Contribution to Conference Proceedings

**Di Marco M**, Mordenti P, Pantaleo MA, Gallerani E, Brandi G, Poggi B, Biasco G, Di Battista M (2001). **New therapeutic strategies in advanced colo-rectal cancer: our clinical experience**. In: ANNALS OF ONCOLOGY, vol. 12, ISSN: 0923-7534

Abstract in to Conference Proceedings (2000)

Biasco G, **Di Marco M**, Akim R Taken from. (2000). **"Adjuvant" treatment in pancreatic tumors.** In: Therapies of pancreatic diseases and portal hypertension. Book of proceedings of the Postgraduate course.

1999 - Contribution in volume (Chapter or Essay)

Biasco G, **Di Marco M** (1999). **"Barret's esophagus."** In: (edited by): G. Ferrini, Gastroesophageal Reflux Disease. p. 63-69

Abstract in to Conference Proceedings (1999)

Mordenti P, Poggi B, Casadei D, **Di Marco M**, Tamberi S, Bonarelli S, Baroncini S, Biasco G (1999). **Oxaliplatin (OHP) in advanced colorectal cancer (ACC): safety and Toxicity.** In: The National Congress of Medical Oncology. Rome, 24/28 October 1999, vol. 1

Abstract in to Conference Proceedings (1999)

Fabbri M, Casadei S, **Di Marco M**, Ridolfi L, Albertini P, Riva N, Ibrahim T, Ridolfi R, Biasco G, Amadori D (1999). **Subcutaneous IL-2 + NSAIDs treatment in advanced NSCLC patients: preliminary data on survival and lymphocytary immunodeficit**. In: 1st National Congress of Medical Oncology, 1999. Rome, 24/28 October 1999, vol. 1

Abstract in to Conference Proceedings (1999)

Brandi G, Manfredi R, Calabrese C, Pisi A, Di Febo G, **Di Marco M**, Di Bari MA, Cenacchi G (1999). **HIV enteropaty: undescribed ultrastructural changes of duodenal mucosa and their regression after triple antiretroviral therapy and case report.** In: SEVENTH EUROPEAN CONFERENCE ON CLINICAL ASPECTS AND TREATMENT OF HIV-INFECTION. LISBON, PORTUGAL.

Abstract in to Conference Proceedings (1999)

Biasco G, **Di Marco M**, Akim R (1999). **Adjuvant chemotherapy in pancreatic and biliary cancers,** extrats from the book of acts: "". Bologna, 12 November 1999; In: (by): Liguori L, Verdecchi GM, Cucchi MC, Multimodal treatment of mechanical jaundice in oncological disease: indications, limits and perspectives. Bologna, 12 November 1999

1999 - Contribution to Conference Proceedings

Tamberi S, Gallerani E, Bazzocchi R, Zompatori M, Martinelli G, Schiavina M, **Di Marco M**, Brandi G, Biasco G (1999). **Carboplatin (CBDCA) and Paclitaxel (TAX) as induction chemotherapy in stage IIIA- IIIB in non small cell lung cancer (NSCLC).** In: ECCO 10 - The European Cancer Conference Vienna. EUROPEAN JOURNAL OF CANCER, vol. 35, Suppl. 4, ISSN: 0959-8049, Vienna, 12-16 September 1999

1998 - Contribution to Conference Proceedings

Tamberi S, Mordenti P, Poggi B, **Di Marco M**, Casadei S, Bazzocchi R, Biasco G (1998). **Carboplatin (CBDCA) and Paclitaxel (TAX) in advanced non small cell lung cancer (NSCLC): preliminary results”**; Vol.,: (abstract 239);. In: A Journal of Experimental and Clinical Oncology. TUMORI, vol. 84, ISSN: 0300-8916

Bologna, March 14th 2021 Dr. Di Marco Mariacristina

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_